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Neoadjuvant systemic therapy (NST) for early breast cancer achieves equivalent 
survival outcomes and offers several advantages over adjuvant treatment2. In 
patients with a good clinical response, less extensive surgery can be considered and 
superior cosmetic outcomes can be achieved3. Primary systemic therapy also 
provides opportunity to study the clinical and molecular evolution of cancers as they 
respond to various chemotherapeutic and targeted agents. NEONAB was a phase II, 
single arm, multi-centre clinical trial of neo-adjuvant epirubicin, cyclophosphamide 
and nano-particle bound paclitaxel (nab-paclitaxel). Ethics approval for the projects 
contained within this thesis was sought and granted by Deakin University Human 
Research Ethics Committee approval number: 2013-068. 
It contained several research objectives. Namely, to assess the feasibility and safety 
of tailoring this regimen of NST to patients using a molecular tool in addition to 
traditional clinico-pathological criteria, to examine the accuracy of magnetic 
resonance imaging of the breast post NST and, finally, to interrogate pre and post 
treatment tumour samples for markers of resistance and response.  
The first chapter in this thesis reports the clinical outcomes for the primary cohort in 
the NEONAB trial, including an assessment of the feasibility of using the Oncotype 
DX® Recurrence Score (RS) and the safety and feasibility of nab-paclitaxel in the 
neoadjuvant setting. The study found that, in this clinically and molecularly defined 
cohort of patients, high response rates were achieved compared to historic controls. 
In addition, the use of nab-paclitaxel in place of a standard taxane was safe, with 
acceptable rates of CT CAE4 grade 3/4 toxicities. We concluded that the use of 
genomic signatures such as Oncotype DX® RS to guide neoadjuvant chemotherapy 
in hormone receptor (HR) positive breast cancer warranted further investigation in 
larger, prospective clinical trials. Similarly the use of nab-paclitaxel in this setting 
was worthy of further consideration and since the completion of our trial, phase III 




data has now been released confirming its safety and supporting its efficacy in early 
stage disease5,6. 
Where the use of chemotherapy, hormone therapy and other targeted agents is 
largely determined by specific patient and pathological characteristics, the extent of 
surgery following NST depends on the radiological characteristics and response of 
the tumour. Magnetic resonance imaging (MRI) is the most sensitive imaging 
modality used in staging primary breast cancer7. Consensus guidelines state MRI 
may be used to reassess disease following NST and prior to surgery but relative cost 
and accuracy in this setting has limited its use8. The aim of our second project was 
to investigate the accuracy of post treatment MRI in predicting pathological 
complete response (pCR) and extent of residual disease in the NEONAB primary 
cohort and specific subgroups. Based on previous literature we hypothesised MRI 
would be most accurate in the HER2 positive and triple negative breast cancer 
(TNBC) subgroups. Due to the limited sample size, subgroups defined by HR status 
and Oncotype DX® Recurrence Score, human epidermal growth factor type 2 
receptor (HER2) and Ki67 immunohistochemical (IHC) profile were subject to 
exploratory analyses only. Our results indicated MRI may be more accurate for 
predicting pCR in HER2 postive disease and in tumours with a high Ki-67 index. We 
concluded MRI has a role in the assessment of residual disease following NST but 
the underlying clinicopathological characteristics of the primary tumour should be 
used to inform our interpretation of the imaging results.  The publication of this 
study comprises the thesis’ second chapter. 
Advances in high throughput sequencing have allowed researchers to describe the 
genomic landscape of early breast cancer in extraordinary detail.  Gene expression 
profiles in HR positive disease and HER2 status as defined by IHC or in-situ 
hybridisation techniques are used in the clinic to guide treatment decisions, 
however, no such predictors exist for TNBC.  Until recently, studies that have 
included the assessment of residual disease had focused on gene expression 
changes or been limited to targeted panels of fewer than two hundred genes9-11. 




Pathological complete response is the most common primary outcome of these 
studies, few contain clinical outcome data such as disease recurrence or breast 
cancer mortality. We hypothesised whole-exome sequencing of paired samples will 
provide further insights into the clonal evolution of TNBC and reveal novel genomic 
alterations that improve our understanding of the mechanisms of chemotherapy 
resistance. Fifteen women with TNBC who were treated in NEONAB’s primary 
cohort consented to the collection of pre and post therapy tumour samples and 
were uniformly treated with epirubicin, cyclophosphamide and nab-paclitaxel. 
These samples have detailed clinical annotation including baseline characteristics, 
recurrence and survival outcomes. The aim of our translational work was to 
investigate these samples for genomic markers associated with response or 
resistance to anthracycline/taxane chemotherapy.  
Analyses of the paired samples enabled us to examine the evolution of resistant 
cancers under the selective pressure of chemotherapy. Our study described the 
presence of a mutational signature, detected in 75% of our samples, that implied 
homologous repair deficiency (HRD) was present in these tumours. In addition, 
three of the five residual disease samples exhibited significant enrichment for 
alterations in ATM signaling, further suggesting DNA repair pathways were defective 
in these cancers. No significant differences in mutation burden or other 
commonalities in gene or gene pathways were identified in the patients who 
achieved pCR compared to those who did not. This reflects the known 
heterogeneity of TNBC and the limitations of our study’s small patient population.  
Taken together, the results of our studies support further investigation into genomic 
and radiological predictors of response to neoadjuvant chemotherapy. It is 
increasingly clear, however, that within the TNBC subtype, the level of genomic 
heterogeneity makes the discovery of a single predictive signature unlikely. Future 
advances in the treatment of TNBC using targeted therapies will likely rely on a 
personalised medicine approach.  
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Introduction: Genomics and the Neoadjuvant Systemic 
Treatment (NST) of Early Breast Cancer (EBC) 
 
1.1 Breast Cancer: a brief overview 
Breast cancer is a common disease, it affects 1 in 9 Australian women, accounts for 
13.2% of all new cancer diagnoses and 6.5% of cancer deaths12. Broadly, the disease 
is divided into three sub-types defined by IHC staining for oestrogen (ER) and 
progesterone (PR) receptors and over expression of HER2 assessed by in situ 
hybridisation methods. Depending on an individual tumour’s expression of these 
receptors it may be termed HR positive, HER2 positive or a TNBC. Advances in 
chemotherapy, hormone therapies and targeted HER2 therapies have drastically 
improved survival for most breast cancer patients. Unfortunately, the ~15-20% of 
breast cancer patients diagnosed with TNBC have seen far fewer gains than their HR 
and HER2 positive counterparts. This is due, in part, to TNBC’s typically more 
aggressive biology, but also the underlying molecular heterogeneity of the subtype, 
which has posed significant challenges to the discovery and development of new 
therapies. Due to the potential for systemic dissemination and established 
equivalent survival outcomes, many TNBCs are now treated prior to surgery with 
neo-adjuvant systemic therapy comprised of combination anthracycline/taxane 
chemotherapy2.  
1.2 Endpoints: use of pathological complete response in NST studies 
Pathological complete response (pCR) is commonly used as a measure of efficacy in 
studies that investigate genetic profiling and NST in early breast cancer. There is, 
however, no standardised definition of pCR. Pathological complete response may 
refer to response in breast only, or encompass response in breast and axillary 
nodes, and may or may not include the presence of residual non-invasive disease 
(Table 1). Due partly to this lack of a unifying definition, recent large analyses of 
neoadjuvant breast cancer trials have not been able to validate pCR as a surrogate 




for survival13-15. Despite this, pooled analyses have shown pCR defined as ypT0ypN0 
(no invasive disease in breast or nodes) is more closely associated with survival than 
other definitions and its prognostic value is strongest in patients with triple negative 
breast cancer14-16. The use of pCR as an endpoint in the study of predictive genomic 
signatures allows investigators to identify and analyse the molecular differences 
between chemo-sensitive and chemo-resistant cancers.  
Table 1. Various Definitions of Pathologic Complete Response (pCR) in Primary 
Systemic Therapy (NST) Clinical Trials. 
Pathologic response 
Breast only: ypT0 regardless of nodal status  
Breast only: ypT0 ypTis regardless of nodal status  
ypT0, ypN0 only  
ypT0 ypTis, ypN0  
Chevallier classification17 
Class 1, disappearance of all tumor either on macroscopic or microscopic 
assessment. 
Class 2, presence of in situ carcinoma in the breast, no invasive tumor, and no tumor 
found in the lymph nodes.  
Class 3, presence of invasive carcinoma with stromal alteration, such as sclerosis or 
fibrosis. 
Class 4, few modifications of the tumoral appearance.  
Sataloff Classification18 
Primary site response:  
T-A) total or near total therapeutic effect;  
T-B) subjectively >50% therapeutic effect but less than total or near total;  
T-C) ≤50% therapeutic effect, but effect evident;  
T-D) no therapeutic effect 
Axillary lymph node response:  
N-A) evidence of therapeutic effect, no metastatic disease 
N-B) no nodal metastasis or therapeutic effect 
N-C) evidence of therapeutic effect but nodal metastasis still present 
N-D) viable metastasis disease, no therapeutic effect. 
The modified regression grading (RG) system19 
Grade 5, no microscopic evidence of residual viable tumor cells (invasive or 
noninvasive) in breast and nodes 
Grade 4, no residual tumor in breast tissue, but involved nodes. 
Grade 3, only residual noninvasive tumor in breast tissue irrespective of lymph node 
involvement 
Grade 0 to 2, for all remaining scenarios. 




1.3 Magnetic Resonance Imaging (MRI) in neoadjuvant studies of EBC 
Magnetic resonance imaging  is the most sensitive imaging modality used in the 
detection and primary staging of breast cancer and has greater accuracy than 
ultrasound (US) or mammography in reassessing residual disease after NST7,8,20-24. 
Recent data suggest the accuracy of MRI is dependent on pre-treatment breast 
cancer subtype, with higher sensitivity and specificity in TNBC or HER2 positive, HR 
negative cancers25-32. Other biomarkers such as Ki67 proliferation index and 
radiological phenotype may also affect the accuracy of MRI in the neoadjuvant 
setting29,33-35. There is, however, a paucity of data regarding the role of genomic 
signatures in this setting and how they may inform the interpretation and use of 
MRI post-NST36.  
1.4 Methods used for the investigation of genes and gene expression in 
EBC studies 
Beginning the first decade of this century, a concerted effort has been made to 
investigate genetic signatures capable of predicting breast cancer response to 
neoadjuvant chemotherapy37-46. Many of the earlier studies utilised gene expression 
profiling where RNA was extracted from a training set of pre-chemotherapy patient 
samples and tumour gene expression analysed using either custom built or 
commercially available cDNA microarrays. Multigene signatures associated with 
response were identified and validated for their predictive capabilities in a separate 
set of patients, either reserved for this purpose from the study’s initial population or 
accessed via publicly available databases47. While DNA microarrays require fresh 
tumour tissue, subsequent studies have also utilised real time reverse transcriptase 
polymerase chain reaction (RT-PCR) performed on formalin-fixed paraffin-
embedded (FFPE) tumour specimens to achieve similar results41,48 Quantifying 
transcripts expressed at either very low or very high levels was more accurately 
achieved using RT-PCR than microarrays49.  Once public databases were sufficiently 
populated with gene expression data sets from earlier trials, investigators could 
access these resources to develop and test predictive models in larger 
populations9,50-55. Similar techniques have been applied to the study of matched 




tumour pairs taken from individual patients prior to, during and after neoadjuvant 
systemic therapy56-59. This research has detailed the evolution of gene expression 
profiles in response to treatment and is discussed in more detail below. 
Other studies have focused on the tumour genome itself. High-throughput 
sequencing is increasingly being employed to investigate pre-treatment samples, 
identify changes in potential driver mutations brought about by the selective 
pressures of neoadjuvant treatment and define molecular characteristics of residual 
disease11,60,61.  
 
1.5 High throughput sequencing in EBC 
Recent advances in high throughput sequencing have enabled researchers to 
interrogate the mutational profiles and genomic alterations of EBC at lower cost and 
in finer detail49. A number of findings have been consistent across studies. First, 
primary breast tumours contain a dominant clone that comprises 50-95% of the 
tumour62,63. Second, significant genetic diversity exists within EBC as a whole and 
also within its molecularly defined subtypes. Ninety-three driver mutations have 
been identified but these occur with low frequency and, in TNBC, studies including 
RNA expression analyses have shown only 36% are expressed61,63-65. The majority of 
the tumours sequenced were not annotated with clinical data and therefore the 
clinical significance of most of these mutations is not known. 
Only a few single genes have been associated with response to NST. Ellis et al. found 
proliferation was suppressed by treatment with an aromatase inhibitor in tumours 
that harboured mutations in GATA3. Two studies have found copy number 
alterations (CNAs) associated with relapse and residual disease after treatment with 
neoadjuvant hormone or chemotherapy60,61. Park et al identified KRAS mutation, 
enriched in less than 10% of tumours, predicted early failure following NST66.  TP53 
is commonly mutated in primary breast cancers but its predictive value is unclear60. 
Hoadley et al found TP53 mutation was associated with pCR in HER2+ cancers 
whereas other studies have shown gene expression signatures of TP53 were 




predictive of response but presence of the mutated gene was not53,67-69. Equally, 
investigation into the predictive value of PIK3CA mutation in HER2 positive breast 
cancer has produced mixed results. Despite promising pre-clinical data, patients 
with PIK3CA wildtype HER2 positive breast cancer do not derive additional benefit 
from traztuzumab compared to their PIK3CA mutated counterparts70. In the 
neoadjuvant setting, PIK3CA mutation has been associated with lower rates of pCR 
in the NeoALTTO study but not CHER-LOB or CALGB 4060169,71,72.  The increased 
availability and application of high throughput sequencing to the study of EBC has 
the potential to yield new predictors of response and survival. However, due to the 
low frequency of driver mutations and high level of genetic diversity in EBC, these 
may be multigene pathways rather than single genes60,61,71,73-77. 
1.6 Gene expression signatures and molecular subtyping  
Investigators have been successful in building gene expression signatures that 
predict for pCR following NST. With a discovery set of eighty two patients Hess et al. 
developed the DLDA 30, a thirty gene expression profile that predicted sensitivity to 
neoadjuvant paclitaxel, fluorouracil, doxorubicin and cyclophosphamide (T-FAC)46. 
In a separate study, Peintinger et al. showed that DLDA 30 correlated with residual 
cancer burden after six months of NST44. This signature was then evaluated in a 
randomized trial and found to predict pCR in patients treated with T-FAC but not in 
patients who were treated with fluorouracil, doxorubicin and cyclophosphamide 
alone78. Naoi et al. developed a seventy gene signature to predict pCR post 
fluorouracil, epirubicin and cyclophosphamide with similar positive and negative 
predictive values to the DLDA 3079. In order to validate the utility of various 
signatures in a larger population, Lehmann et al. conducted a meta-analysis of 
breast cancer derived gene expression profiles in 31 public breast cancer data sets. 
This meta-analysis identified two profiles, BRmet50 and PMID18271932Sig33, able 
to predict sensitivity to neoadjuvant chemotherapy in over nine hundred patients 
from the five public data sets with pCR data available53.  As already stated, there is 
controversy surrounding the use of pCR as a surrogate for long term outcomes. 




Several studies have also correlated their gene signatures directly with survival 
endpoints. Multiple profiles have been shown in retrospective studies to predict 
distant metastasis free survival50,51,53,80, as well as disease free or recurrence free 
survival40,81. 
To better predict the biological behavior and prognosis of breast cancers several 
gene expression profiles were designed to classify patients into molecular subtypes. 
Examples of these classifiers include Mammoprint and Blueprint82, Endoprint50 and 
PAM5083.  Response to chemotherapy has been shown to vary significantly 
according to subtype and some molecular subtype classifications are able to predict 
pCR82,84,85. Recognising this, investigators have focused on subsets of molecularly 
defined patients and developed signatures that predict response to specific 
therapies within these groups86,87.  In hormone receptor positive disease 
Mammaprint and Oncotype DX® Recurrence Score are gene expression profiles now 
used in the clinic to predict benefit from adjuvant chemotherapy88-91. 
 
1.7 Mutational signatures in breast cancers 
In 2013 Alexandrov et al published a seminal paper that described the mutational 
signatures active in cancer in Nature92. This publication has reorientated the field of 
cancer genomics to focus on the processes that influence the acquisition of DNA 
alterations in addition to the alterations themselves.  These signatures reflect 
inherent biases active in all cells across an individual’s lifetime as well as external 
influences such as industrial exposures or cigarette smoking. Initially these 
mutational signatures described base substitutions, then insertion/deletions and 
subsequently further signatures were identified that described copy number 
changes and other large genomic rearrangements93,94. Initially five signatures were 
identified as active in breast cancer, this was expanded to 12, possibly 13 signatures 
in a major effort that involved whole genome sequencing of 560 breast 
cancers65,73,95,96. Given the power of these analyses, further signatures are not likely 
to be identified. The potential clinical utility of these signatures is already being 




explored. A combination of 6 signatures termed ‘HRDetect’ has been developed that 
expands the subgroup of breast cancers with homologous repair deficiency likely to 
respond to targeted therapy with polyADP ribose polymerase (PARP) inhibitors from 
the known 3-5% of patients with germline BRCA-null tumours to up to 22% of all 
breast cancers94. Whilst previous reports have described alterations in gene 
pathways and specific genes after chemotherapy for breast cancer the effect of 
chemotherapy on mutational processes needs to be more fully explored11. A study 
of four advanced breast cancer patients showed some mutational signatures are 
stable throughout early and advanced disease whereas others are acquired later in 
the tumour’s evolution97. In a project examining primary breast tumours paired with 
later local relapse or metastatic lesions, Yates et al. demonstrated the mutational 
processes active within the primary tumour still drive mutagenesis later in the 
advanced cancer clones98. The question of whether the mutational processes 
operating in the primary tumour remain stable in residual disease after neoadjuvant 
therapy is addressed in our research project. 
1.8 Clonal Evolution of Breast Cancers 
In a whole genome and targeted sequencing project involving multiple biopsies 
taken from individual primary breast cancers, Yates et al. demonstrated the extent 
of sub-clonal heterogeneity varies from patient to patient and different subclones 
are spatially separated within a tumour99. Gao et al. further demonstrated that, in 
TNBC, between one and three major clonal populations can be identified in a single 
lesion and copy number aberrations occur early in a tumour’s evolution100. A further 
study of primary and metastatic lesions by Savas et al. showed the subclonal 
structure present in the primary lesion of an aggressive TNBC was present in all 
future metastatic lesions101. In addition, this particularly aggressive cancer was the 
more homogenous in terms of its subclonal structure compared to less aggressive, 
hormone receptor positive cases also studied. In this paper, treatment appeared to 
affect sub-clonal structure. Emergence of a clone containing a mutation likely to 
confer resistance to fluorouracil chemotherapy was noted, as well as separate 




clones with ESR1 mutations known to confer resistance to hormone therapies102. 
The weight of evidence in studies of subclonal structure of breast and other cancers 
suggest that it is the emergence of pre-existing alterations in genes and gene 
pathways that result in treatment resistance rather than treatment induced 
alterations to drug targets97,98,101,103.  
 
1.9 Analyses of paired pre- and post-NST breast cancers  
Analyses of paired pre- and post-treatment samples from chemo-resistant tumours 
have revealed changes in mutational and gene expression profiles occurring in 
response to the selective pressures of neoadjuvant chemotherapy. Early studies in 
heterogeneous populations of breast cancer patients demonstrated the feasibility of 
examining the genetic profiles of paired samples and established that appreciable 
changes in gene expression did occur.43,45 These studies also demonstrated that 
gene expression profiles of pre and post-treatment samples from the same patient, 
whilst altered, retained greater similarity than post treatment sample comparisons 
between tumours from different patients38,43,45.  
More recent studies of paired samples focused on the discovery of expression 
signatures that can predict response or resistance to specific therapies58,59. 
Subsequent work has attempted to identify the functional implications of the 
observed genetic changes and isolate potential mechanisms of resistance that may 
then be targetable with novel therapeutic agents 10,11,56,57,83,104. Many of these studies 
have also investigated response by molecular subtype and found that NST can 
induce sufficient alterations in gene expression to cause a change in subtype 
between primary tumour and residual disease10,11,59,83. Gene expression signatures of 
residual disease also have the potential to predict clinical outcomes and identify a 
subpopulation of patients at high risk of recurrence or death who may benefit from 
trials of novel treatments57,83.  
 




1.10 Genes and gene signatures of interest in triple negative breast cancer  
Several gene signatures have been developed that are predictive of response only in 
specific clinico-pathologically or molecularly defined subtypes9,52. Expression profiles 
of genes involved in proliferation pathways have been associated with response in 
HR positive but not HR negative breast cancer9,51. Multiple studies have identified 
associations between tumour infiltrating lymphoctyes identified by 
immunohistochemistry, immune related gene expression signatures and response in 
HER2+ disease51,83,104. In TNBC, driver mutations occur at low frequencies63. There 
are also fewer gene sets associated with prognosis and response in TNBC compared 
with other molecular subtypes and this has likely underscored the difficulty in 
developing predictive assays for these patients9. 
Identifying those TNBC patients at higher risk of relapse following NST who may 
benefit from further treatment targeted at underlying resistance mechanisms is a 
research priority. Gene expression profiling of TNBC has demonstrated that there is 
significant diversity within the subtype. In pre-clinical work Lehmann et al. 
developed seven molecular sub-classifications for TNBC which have since been 
shown in a cohort of TNBC patients from MD Anderson to predict for differential 
response to NST54,105. By investigating patients with residual disease following NST, 
Yu et al developed a seven gene signature to identify a subset of TNBC patients at 
higher risk of relapse106. A study utilizing next generation sequencing (NGS) found 
higher copy number alterations were associated with relapse and gene pathways 
were more powerful at predicting pCR than single gene mutations60.  Paired sample 
analysis has the advantage of demonstrating changes in genetic profile between the 
primary tumour and residual disease after exposure to NST. Balko et al. performed 
gene expression profiling and targeted NGS on paired pre and post-NST samples 
from TNBC patients and found gain or enrichment in PI3K/mTOR & cell cycle 
regulator genes and TP53, MCL1 & MYC amplifications in residual disease. 
Importantly, in this study, >90% of the genetic changes identified could potentially 
be targeted with currently available therapies. Using whole exome sequencing Jiang 




et al. found alterations in the AR/FOXA1 pathway were associated with a higher rate 
of pCR and were able to define a BRCA deficient subset of TNBC with significantly 
improved survival after anthracycline/taxane chemotherapy77. 
The differential responses to NST seen in TNBC may, in part, be explained by the 
tumour’s interaction with the host’s immune system or by alterations in its 
metabolic pathways. TNBC are relatively immunogenic tumours, on 
immunohistochemical examination a higher proportion of TNBC will have robust T-
cell infiltrates compared to HER2+ or HR+ breast cancers107. Tumours categorized as 
lymphocyte predominant by IHC (LPBC) have higher rates of response to NST and 
improved survival108,109. In TNBC immune related gene signatures have been linked 
to tumour infiltrating lymphocytes and are associated with higher response and 
improved prognosis51,55,110-112. A study of paired pre- and post-treatment TNBC found 
chemo-resistant residual disease was characterized by enrichment in the expression 
of genes involved in metabolic pathways and depletion in the expression of immune 
related genes10. In a separate study Iwamoto et al. also demonstrated an association 
between expression of metabolic genes sets and response and prognosis9. Jiang et 
al. used whole exome sequencing to define a subset of BRCA deficient TNBC. These 
tumours were associated with a higher mutation burden and presented a higher 
load of clonal neoantigens with higher immune cell activity and improved 
response77. Discovery of functionally important mutations, gene pathways or other 
molecular signatures in chemo-resistant disease may identify patients, with 
otherwise poor prognosis, who could benefit from novel therapies that target these 
specific alterations. This could form the basis of hypothesis generating research to 
explore novel therapeutic options in this area of need. 
1.11  Aims of the NEONAB studies 
This thesis is comprised of three studies, each of which addresses a different aspect 
of the NEONAB trial’s research aims. The first chapter reports the clinical outcomes 
of the study whose main purpose was to verify the safety of nab-paclitaxel in the 
neo-adjuvant context and establish whether restricting neo-adjuvant treatment to a 




molecularly selected cohort of breast cancer patients would result in high response 
rates.  The second chapter is comprised of a medical imaging study that assessed 
the accuracy of MRI post-NST to predict pathological response. The aim of this 
project was to provide evidence to help define and inform the use of MRI in the 
neo-adjuvant setting. The third project’s aim was to analyse the molecular profiles 
of TNBCs in NEONAB and study their evolution under the selective pressure of NST. 
In defining groups based on their pathological response it was hoped some 
commonalities could be discovered that may differentiate the responders from 
those who were left with residual disease. Most studies of residual disease are 
retrospective, and include cancers treated with a variety of agents and often with 
little accompanying clinical information. We analysed a cohort of uniformly treated, 
clinically annotated TNBCs, which has provided a clearer  insight into this disease’s 
evolution in response to anthracycline/taxane therapy. A better understanding of 
the molecular signatures of chemosensitive and chemoresistant tumours is 
necessary to the development of new therapies targeting those non-responders and 
equally, potentially de-escalating toxic treatments for those good prognosis patients 
who may not require such intensive treatment.  
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Survival outcomes for early breast cancer patients have improved significantly, with 
the consequence a proportion of today’s patients are likely receiving more 
treatment than is necessary for their individual cancers113. There is, therefore, a 
clinical need to develop predictive tools that can accurately discriminate between 
patients who require therapy from those who can safely avoid treatment. Adjuvant 
treatment of early hormone receptor (HR) positive breast cancer has been refined 
by the use of commercially available gene expression profiles that identify low-risk 
patients who do not benefit from chemotherapy88-90. Current methods of targeting 
neoadjuvant therapy are based on clinicopathological criteria. The NEONAB trial 
assessed the potential utility of a genomic tool, the Oncotype DX® Recurrence Score 
(RS), in addition to existing biomarkers, to guide NST. The trial also assessed the 
safety and feasibility of the drug nab-paclitaxel in place of standard neo-adjuvant 
taxane therapy. The trial recruited women with Stage II-III breast cancer, including 
HER2 positive, HR positive and TNBC. HR positive cancers underwent RS testing and 
patients with a low or intermediate RS (<25) were excluded from the primary 
cohort. We found the use of nab-paclitaxel and restricting our HR positive 
population to patients with high RS (≥ 25) resulted in high response rates and an 
acceptable toxicity profile. Our results support further investigation into the use of 
nab-paclitaxel and gene expression signatures in the neo-adjuvant setting.  
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This study evaluated the feasibility and likelihood of achieving high response rates in 
stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and 
histopathological features, and Oncotype DX® Breast Recurrence Score. 
Patients and methods:  
Fifty-one patients with stage II or III breast cancer were enrolled. The primary cohort 
comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2) 
positive; 15 triple-negative; and 10 hormone-receptor (HR)-positive, HER2-negative 
tumours; with recurrence scores greater than or equal to 25. Patients were treated 
with epirubicin and cyclophosphamide, followed by nab-paclitaxel, with the addition 
of trastuzumab if HER2 amplified. Patients with HR-positive, HER2-negative tumours 
and a recurrence score <25 (n=8) were treated in an exploratory cohort. One patient 
did not meet screening criteria, one patient had inadequate tissue for recurrence 
score testing and one patient withdrew consent. The primary endpoint was 
pathological complete response in the breast.  
Results: 
Median age was 51 years (35–77). The pathologic complete response rates in the 
breast were: overall 55% (n = 22), HER2-positive 80% (n = 12), triple-negative 46% (n 
= 7) and HR-positive, HER2-negative 30% (n = 3). Grade 3 or 4 adverse events 
included febrile neutropaenia (8%), neutropaenia (18%), sensory neuropathy (5%), 
deranged transaminases (5%), fatigue (2%), diarrhoea (2%), pneumothorax (2%). 
Conclusions: 
Epirubicin and cyclophosphamide with nab-paclitaxel resulted in a high rate of 
pathological complete response, demonstrating that tailored neoadjuvant therapy 
using a genomic recurrence score is feasible and warrants further investigation. 
Trial registration: Registered on Clinicaltrials.gov on 27 March 2013: NCT01830244.  





In early breast cancer, neo-adjuvant or primary systemic therapy achieves 
equivalent survival outcomes and offers several advantages over adjuvant 
treatment 2. In patients with a good clinical response, less extensive surgery can be 
considered and superior cosmetic outcomes can be achieved 3. Primary systemic 
therapy also provides opportunity to study the clinical and molecular evolution of 
cancers as they respond to various chemotherapeutic and targeted agents. 
Current methods to identify patients most likely to benefit from primary systemic 
therapy are based on clinicopathological criteria, including immunohistochemical 
profile. Additionally, the proportion of cells staining for nuclear antigen Ki67 
provides an indication of a tumour’s rate of proliferation 114. In hormone receptor 
(HR)-positive cancers, a Ki67 index < 15% can be a surrogate for discrimination 
between molecularly defined luminal A and luminal B subtypes 115. This is clinically 
important, as luminal A cancers are unlikely to respond to chemotherapy. The 
clinical utility of Ki67 is, however, limited, as accurate measurement is confounded 
by tumour heterogeneity and inter-operator variability. 
Gene expression signatures are promising tools, but their ability to discriminate 
between responders and non-responders to neoadjuvant chemotherapy has not 
been established 2. In contrast, adjuvant treatment of HR-positive disease has been 
refined by the use of commercial genomic signatures that classify patients into 
prognostic groups and identify those who may be safely treated with endocrine 
therapy alone 88,89. The Oncotype DX® Breast Recurrence Score (RS) is a molecular 
assay comprising 21 genes associated with tumour cell proliferation and hormonal 
response. It was developed and validated using archived tumour samples as a 
predictor of disease recurrence and benefit from chemotherapy in women with HR-
positive, lymph node (LN)-negative breast cancer 116,117. It has since been validated 
in women with HR-positive, LN-positive disease and prospectively validated in two 
phase III trials confirming that women with HR-positive, human epidermal growth 




factor receptor type 2 (HER2)-negative breast cancer and low RS may safely omit 
adjuvant chemotherapy 89,118-120. In this study we investigated its use in the 
neoadjuvant setting to aid decision making for eligible HR-positive patients. High 
risk RS (≥31) has previously been correlated with poor clinical response to neo-
adjuvant endocrine therapy 121. We used a more conservative RS of 25 or higher to 
select HR-positive patients to be treated with chemotherapy. Since the design of our 
trial was finalised, based on newer clinical data, a cut off of equal to 25 or higher has 
become the standard used. No patient in our trial had an RS of exactly 25 and 
therefore the results would not have been altered had the now accepted standard 
definition been used. It is well established that the addition of taxanes to 
anthracyline based adjuvant chemotherapy confers a survival advantage in TNBC1. 
The addition of a taxane to neoadjuvant chemotherapy has improved pathological 
complete response (pCR) rates 122. Owing to its ease of administration and efficacy, 
nab-paclitaxel is used in the treatment of metastatic breast cancer 123,124. In 
randomized studies it has resulted in higher response rates (RR) and acceptable 
toxicity compared with 3-weekly solvent-based paclitaxel and higher disease control 
rates and prolonged progression-free survival compared with docetaxel. Nab-
paclitaxel does not have an established role in early breast cancer and was included 
in this study as an investigational agent. Pilot and phase II studies have 
demonstrated safety and feasibility of nab-paclitaxel as an adjuvant therapy 125-127. 
Small neoadjuvant trials have combined nab-paclitaxel with anthracycline and non-
anthracycline based regimens and demonstrated pCR rates of 17–58% with 
acceptable safety and tolerability 128-131. Gepar-septo, the first phase III randomized 
trial of neoadjuvant nab-paclitaxel versus solvent-based paclitaxel recently reported 
a significantly higher pCR rate (38% vs 29% P<0.001) in the nab-paclitaxel arm 132. 
We hypothesised tailoring neoadjuvant therapy to a molecularly defined population 
using RS in addition to traditional clinico-pathological criteria would result in high 
pathological response rates. In addition we assessed the safety of nab-paclitaxel in 
early breast cancer.  




2. Patients and methods 
2.1 Study design 
NEONAB was a multicentre open-label phase II study (Clinicaltrials.gov 
#: NCT01830244). The primary objective was the pCR rate in the breast. Secondary 
objectives included pCR in breast and axillary LN, pCR and near complete response 
(nCR) combined, disease-free survival (DFS), rate of breast conserving surgery, 
tolerability, and safety of the investigated regimens. This study was reviewed and 
approved by the relevant ethics committees. All patients signed informed consent. 
2.2 Patient eligibility 
Patients with previously untreated stage II or III, unilateral, histologically confirmed 
invasive breast cancer and an Eastern Cooperative Oncology Group (ECOG) 
performance status ≤ 1, were eligible. All tumours were tested locally for oestrogen 
receptor (ER) and progesterone receptor (PR) status, considered positive if ≥1% of 
tumour cells stained for ER and/or PR. HER2 status was also assessed by 
immunohistochemistry and in situ hybridisation. Other inclusion criteria were age ≥ 
18 years, normal left ventricular ejection fraction, and adequate haematopoietic, 
liver and renal function. 
Exclusion criteria included distant metastases, history of ipsilateral breast cancer, 
previous radiation therapy to the breast, previous anthracyclines or taxanes, serious 
cardiovascular, hepatic, neurologic or renal comorbid conditions, pregnancy or 
lactation, and male sex. 
2.3 Treatment 
An overview of treatment allocation is given in Figure 1. Patients with HER2-
negative, HR-positive cancers had the RS assay performed according to screening 
requirements. Patients with HR-positive cancers with RS<25 were treated in an 
exploratory cohort with primary surgery or neoadjuvant hormone or chemotherapy 




at the discretion of the treating physician. The primary cohort consisted of patients 
with HER2-negative, HR-positive, RS ≥25 tumours, HER2-positive tumours and triple 
negative breast cancers (TNBCs). They received epirubicin 90 mg/m2 and 
cyclophosphamide 600 mg/m2 (EC) every 3 weeks for 12 weeks; followed by nab-
paclitaxel 125 mg/m2 days 1, 8, and 15 every 4 weeks for 12 weeks. Trastuzumab 
was added to nab-paclitaxel for HER2-positive patients at an initial dose of 8 mg/kg 
and subsequent doses at 6 mg/kg every 21 days for a total of 12 months.  
Chemotherapy was withheld for any grade ≥2 toxicity with the exception of an 
absolute neutrophil count ≥0.9 x 109/L. For ≥ grade 3 neutropaenia, granulocyte 
colony stimulating factor (G-CSF) was added. Any grade 4 infections or febrile 
neutropaenia required a dose reduction and subsequent administration of G-CSF. 
Grade ≥3 non-hematologic toxicities mandated a 20% dose reduction. Nab-
paclitaxel was withheld for grade ≥2 neuropathy until resolved to ≤ grade 1. 
Trastuzumab was continued if chemotherapy was delayed. 
2.4 Radiology 
All patients underwent ultrasound of the breast and axillary LN and mammogram 
before treatment. Magnetic resonance imaging of the breast was also performed 
before and after primary systemic therapy. The utility of MRI in assessing residual 
disease is reported in a separate article. 
2.5 Post-chemotherapy treatment 
Patients underwent mastectomy or breast conserving surgery, and sentinel node 
biopsy or axillary dissection after discussion with their surgeon. Postoperative 
radiotherapy and adjuvant endocrine therapy for HR-positive patients were 
determined by the treating physician. All cases were presented at a breast cancer 
tumour board/multidisciplinary meeting. 




2.6 Endpoint assessment 
Residual tumour was evaluated microscopically by designated local pathologists 
according to predefined pathology criteria. Central review was not conducted. 
pCR in the breast was defined as ypT0/is ypN0-3, no evidence of invasive tumour 
cells in the surgical breast specimen, with residual ductal carcinoma in situ 
permitted. Invasive or non-invasive disease in LN were allowed. nCR was defined as 
the presence of scattered tumour cells only 133. 
DFS was defined as the time from registration on the trial until documented 
evidence of breast cancer recurrence or death from breast cancer. Primary tumour 
progression during neoadjuvant treatment was not considered an event. Patients 
withdrawing consent or lost to follow-up were censored at the date of last contact. 
2.7 Safety assessment 
Complete blood count and metabolic profiles were assessed at every treatment 
cycle. All dose reductions, delays, and adverse events (AE) were reported. The 
Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0, was used. 
2.8 Statistical methods 
In previous studies of neoadjuvant therapy, pCR have ranged from 12 to 30% 
14,129,133. Accordingly, the RR for the null hypothesis (uninteresting rate) was set at 
30% and for the alternative (worthy of further study) at 50%. A single-stage binomial 
design was planned to discriminate between overall pCR rates of 30% and 50% with 
a type I error of 6% and 87% power. This required a total of 40 patients, and if ≥ 17 
patients were to have pCR, the regimen was to be deemed worthy of further study. 
A maximum of 15 patients with HER2-positive tumours or TNBC were allowed. 
The evaluable intention-to-treat population included all patients enrolled with 
HER2- positive, TNBC, and eligible HR-positive breast cancers who received at least 




one cycle of neoadjuvant chemotherapy and at least one post-infusion tumour 
assessment. DFS was evaluated using Kaplan-Meier methods. 
3. Results 
3.1 Patient characteristics 
Between April 2013 and December 2015, 51 patients were enrolled. At 31 
December 2015, the median follow-up was 1.55 years (range 0.96–2.63 years). The 
primary cohort consisted of 40 women (15 HER2-positive, 15 TNBC, and 10 HER2-
negative, HR-positive patients with RS ≥ 25). Baseline characteristics are 
summarised in Table 1. Nine women were in the separate exploratory cohort; Figure 
1. Two patients were treated off study, one withdrew consent, and one was found 
to be ineligible after enrolment. 
Locally assessed high Ki67 (Ki67≥15) did not correlate with a high RS result (RS≥25) 
in five of the 17 (30%) of the patients who had both results available. 
3.2 Efficacy: treatment response 
In the primary cohort, the overall pCR rate in the breast (Table 2) was 55% (n = 22). 
Of these 32.5% (n = 13) were ypT0 ypN0, 12.5% (n = 5) ypT0/is ypN0, and 10% (n = 
4) were ypT0/is ypN+. The pCR rate in the breast alone varied according to subtype: 
HER2 positive, 80% (n = 12), TNBC 46% (n = 7) and HR-positive, HER2-negative 30% 
(n = 3). An additional 10% (n = 4) achieved nCR, defined as residual scattered 
tumour cells only. The combined rate of pCR and nCR in the breast only was 
therefore 65% (n = 26). 
The secondary endpoint, pCR rate in breast and LN, was 45% with similar 
distributions according to subtype (Table 2). 




3.3 Surgery and disease-free survival 
The breast conservation rate was 47.5% (n = 19). Early DFS data are presented in 
Figure 2. The median DFS has not yet been reached. Disease recurred in 18% (n = 7); 
5 TNBC and 2 HR-positive patients. All developed distant disease. Five of these 
patients had residual disease after protocol therapy and 2 had achieved pCR defined 
as ypT0/is.  
3.4 Tolerability and safety 
Overall, treatment was well tolerated, with 97.5% (n = 39) completing protocol 
therapy of EC, and 72.5% (n = 29) patients completing protocol nab-paclitaxel. Most 
of those who did not complete nine doses of nab-paclitaxel according to the 
protocol required minor dose reductions or omissions due to AEs, most commonly 
neuropathy. Overall, the relative dose intensity for nab-paclitaxel was 73%, with 
88% of the cohort (n = 35) receiving ≥85% of the scheduled dose. Common AEs are 
summarised in Table 3. G-CSF was given to 77.5% (n = 31) of patients during EC and 
62.5% of patients during nab-paclitaxel (n = 25) on days 2–7 during weekly therapy. 
The rate of sensory neuropathy with nab-paclitaxel was 55% (n = 22), with most 
events ≤ grade 1. Grade 3 sensory neuropathy occurred in 5% (n = 2). Of the two 
cases of grade 3 transaminase derangement, only one was suspected to be related 
to nab-paclitaxel and both patients recovered to ≤ grade 1. Results for the 
exploratory cohort were not included in the analysis. 
4. Discussion 
Our study investigated the feasibility of tailoring neoadjuvant treatment to a 
population selected on the basis of the RS in addition to traditional 
clinicopathological criteria. The trial required a >50% pCR rate in the breast to meet 
its primary endpoint, and that was achieved. 
Gene profiling in early breast cancer is now part of routine clinical care, with 
commercially available assays to guide adjuvant treatment 88,89,116,119,120. These 




signatures may prove to be of similar use in selecting patients for neoadjuvant 
therapy 134-137. PAM50 successfully identified a subset of HER2-positive patients with 
higher rate of pCR in NOAH, a phase III study of neoadjuvant trastuzumab and 
chemotherapy 84. Similar to NEONAB, but on a larger scale, the I-SPY 2 trial assesses 
neoadjuvant regimens incorporating a gene signature (Mammaprint) in addition to 
HR and HER2 status to define eligibility for primary systemic therapy 138. Two drugs, 
veliparib plus carboplatin, in TNBC and neratinib in combination with standard 
chemotherapy in HER2 positive disease met their pre-specified efficacy endpoints 
and have therefore graduated to testing in phase III trials 139,140. NEONAB used an RS 
≥25 to select HR-positive patients for treatment with neoadjuvant chemotherapy 
and, in this subset, the pCR was 30%. This compares favourably with results from a 
pooled analysis of 6377 women in which 13.3% of patients with ER-positive cancers 
had a pCR defined as ypT0/is ypN0/+ 15. Furthermore, other neoadjuvant studies 
have suggested a correlation between RS and pCR, including a recent phase II study 
of neoadjuvant cyclophosphamide and ixabepilone in HER2-negative breast cancer 
41,141,142. 
In our study, eight HR-positive, HER2-negative patients had RS <25, and one patient 
had insufficient tissue to produce an RS result. These nine patients were excluded 
from the primary cohort and treated with neoadjuvant hormone or chemotherapy 
at their physician’s discretion, potentially sparing them extensive chemotherapy 
from which they were unlikely to derive significant benefit. Interestingly, high Ki67 
was not associated with a high RS result in five of the 17 (30%) of the patients who 
had both results available. This discrepancy adds weight to the argument that Ki67 
should not be used to inform clinical decision making given it has not been validated 
as a predictive biomarker in this setting. 
The high rates of pCR observed in our study may also be due to the use of nab-
paclitaxel in place of traditional taxanes. Compared with treatment with solvent-
based paclitaxel, nab-paclitaxel has resulted in higher rate of radiological response 




in the metastatic setting and achieved a higher rate of pCR in patients with localized 
disease treated with primary systemic therapy 122,132. In our study, nab-paclitaxel, at 
a dosage of 125 mg/m2 delivered weekly, demonstrated acceptable safety. The 
overall RDI for abraxane was 73%, below the recommended 85%, but this included a 
patient whose abraxane was ceased early for reasons unrelated to toxicity. G-CSF 
use was high (62.5%) during abraxane for two reasons, it was added in preference to 
dose reductions or dose delays and some women continued use after commencing 
it during doxorubicin/cyclophosphamide chemotherapy. While nab-paclitaxel 
presents a tolerable and, in terms of response, effective, alternative to standard 
taxane, further research and survival data are required to confirm its role in early 
breast cancer. Further information regarding safety and efficacy is expected in 
another trial (NCT01822314). The low toxicity and high RR achieved in our study, 
together with results of the GeparSepto trial, support ongoing investigation into the 
use of nab-paclitaxel in the neoadjuvant setting 132. 
Limitations of our study include the relatively small sample size and the use of pCR 
in the breast alone as our primary endpoint. Recent large analyses of primary 
systemic therapy in breast cancer have been unable to validate pCR as a surrogate 
endpoint for DFS, event-free survival or overall survival 13,14. In addition, pCR defined 
as ypT0 ypN0 or ypT0/is ypN0 are more closely associated with survival 14-16 than the 
definition used in our study. Although pCR does not definitively predict survival, it is 
a measure of chemoresponsiveness and provides an intermediate assessment of 
efficacy used to facilitate timely development of new therapeutics 16,143. To this end, 
a translational project using high throughput sequencing to interrogate 
preoperative biopsy and surgical specimens from NEONAB participants for markers 
of response and potential mechanisms of resistance is currently under way. 





Tailoring neo-adjuvant therapy with a genomic predictor is feasible, and treatment 
with EC and nab-paclitaxel in this population achieved high RR with an acceptable 
safety profile. 
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AE: Adverse event; EC: Epirubicin and Cyclophosphamide; G-CSF: Granulocyte 
colony-stimulating factor, HER2: Human Epidermal Growth factor Receptor 2; nab-
paclitaxel: Nanoparticle Albumin Bound Paclitaxel; nCR: Near complete response 
(only scattered tumour cells left); pCR: Pathologic Complete Response; DFS: disease-
free survival; RS: Oncotype DX® Recurrence Score; LN: lymph node; TNBC: triple 
negative breast cancer. 
  





Table 1. Baseline characteristics of patients in the primary cohort 
Characteristic n % 
Age, years   
 Median 51 
 Range (35–77) 
ECOG   
 0 39 98 
 1 1 2 
Ethnic group   
 Caucasian 37 93 
 Asian 3 8 
Tumour pathology   
 Adenocarcinoma 1 2 
 Ductal no special type 34 85 
 Inflammatory 1 2 
 Lobular carcinoma 1 2 
 Mucinous carcinoma 1 2 
 Not specified 2 5 
Oestrogen receptor status   
 Negative*  22 55 
 Positive  18 45 
Progesterone receptor status   
 Negative*  27 68 
 Positive  13 32 
HER2 status   
 Nonamplified 25 63 
 Amplified 15 37 
Tumour grade   
 2 14 35 
 3 22 55 
 Not specified 4 10 
Tumour stage+   
 2a 10 25 
 2b 12 30 
 3a 14 35 
 3b 3 8 
 3c 1 2 
* HR status deemed negative if <1% nuclei staining + American Joint Committee on Cancer 
Breast Cancer Staging v.7.ECOG, Eastern Cooperative Oncology Group; HER2, human 
epidermal growth factor receptor type 2 












HR+ HER2- RS 
≥ 25* (n=10) 
Breast only 55(22) 80 (12) 46 (7) 30(3) 
Breast and lymph 
nodes 
45(18) 80 (12) 33 (5) 10(1) 
* HR+ HER2- RS ≥ 25: hormone receptor (HR) positive, HER2 negative with recurrence 
score ≥ 25. HER2+: human epidermal growth factor receptor type 2 positive; TNBC: triple 
negative breast cancer; HR: hormone receptor 
 
Table 3: Most-common adverse events* 
 Any grade Grade 3 or 4 
Adverse event n % n % 
Alopecia 38 95 - - 
Anxiety 6 15 - - 
Bone pain 6 15 - - 
Constipation 9 23 - - 
Deranged transaminases 2 5 2 5 
Diarrhoea 8 20 1 2 
Dysgeusia 6 15 - - 
Dyspepsia 4 10 - - 
Fatigue 27 68 1 2 
Febrile neutropaenia 3 8 3 8 
Gastro-oesophageal reflux 8 20 - - 
Headache 6 15 - - 
Insomnia 7 18 - - 
Nausea 25 63 - - 
Neutropaenia 23 58 7 18 
Sensory neuropathy 22 55 2 5 
Pneumothorax 1 2 1 2 
* Any grade reported for at least 10% of patients or grade ≥3 using CTCAE version 4.0 
reported for any patient. If a patient had more than one adverse event within a 
preferred term, the patient was counted once in the term. 
  



















Figure 2. Kaplan-Meier estimates for disease-free survival. 
 
  





Evaluating the role of Magnetic Resonance Imaging post 
Neoadjuvant Therapy for Breast Cancer in the NEONAB trial. 
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In the management of primary breast cancer, rates of recurrence and survival are 
adversely impacted by incomplete resection. Achieving good cosmetic outcomes 
whilst minimising the need for extensive surgery is a priority for patients and 
surgeons alike113. If NST results in a significant reduction in the size of a breast 
cancer, breast conserving surgery may be offered in place of mastectomy. In order 
to achieve these outcomes, surgeons are reliant on clinical and radiological 
assessments of a breast cancer’s response to NST to inform their surgical plan. 
Magnetic Resonance Imaging (MRI) is the most sensitive imaging modality for the 
staging of primary breast cancer7. Recent studies suggest the accuracy of MRI is 
dependent on pre-treatment tumour characteristics such as HR and human 
epidermal growth factor type 2 receptor (HER2) status, as well as Ki-67 and 
radiological phenotype, but data is limited33,35,26,28. The effect of combining genomic 
biomarkers and MRI findings to predict pathological response has not been 
reported. In this study we examine the accuracy of MRI to predict pCR in the 
NEONAB trial. We performed an exploratory analysis to determine whether MRI 
appeared more accurate in sub-types defined by HR, HER2 receptor status or Ki67 
index. Our findings suggest MRI may be more accurate in HER2 positive and high 
Ki67 index subgroups. The accuracy of MRI in the genomically selected HR positive 
patients with RS ≥25 was not higher than historical controls. We concluded the 




assessment of residual disease after NST and prior to surgery can be aided by MRI if 
the images are interpreted in the context of the pre-treatment tumour’s 
clinicopathological profile.  
  











3.3 Published article 
Evaluating the Role of Magnetic Resonance Imaging post Neoadjuvant Therapy for 
Breast Cancer in the NEONAB trial.  
Manuscript type: original article 
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Accurate radiological assessment of response and residual disease is essential for 
achieving optimal surgical outcomes after neoadjuvant systemic therapy in breast 
cancer. Magnetic resonance imaging (MRI) is the most sensitive imaging modality 
used in the detection and staging of breast cancer7.  Guidelines suggest MRI can also 
be used to assess response to neoadjuvant therapies8. Although several studies, 
including a meta-analysis and a systematic review, have shown MRI has greater 
accuracy compared to ultrasound (US), mammography and clinical examination, 
there is no consensus regarding its utility in the neoadjuvant setting20-24. MRI still 
has the potential to both under and overestimate residual disease. More recent 
data suggests the accuracy of MRI varies according to pre-treatment breast cancer 
subtype defined by the presence or absence of the oestrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor type 2 
(HER2)25-32. These data suggest MRI is most accurate in highly proliferative cancers, 
specifically triple negative breast cancer (TNBC) and HER2 positive, HR negative 
tumours. In addition, the accuracy of MRI may also vary depending on radiological 
phenotype and other biomarkers such as Ki67 proliferation index 29,33-35. 
Current evidence suggests MRI findings post neoadjuvant therapy should be 
interpreted in combination with baseline tumour characteristics36. Existing 
biomarkers such as hormone receptor (HR) and HER2 profiles have proved useful 
but data regarding the utility of molecular biomarkers in this setting are scarce. 
Gene expression profiles are used to predict benefit from adjuvant chemotherapy 
after surgery for early breast cancer88,89. Oncotype DX® recurrence score (RS) is FDA 
approved for this indication and its utility in the neoadjuvant setting is under 
investigation. Other gene expression profiles in use include Mammaprint and 
Prosigna88,144. MRI post neoadjuvant therapy is least accurate in patients with HR 
positive disease but it is unknown if a tumour’s gene expression profile may alter 
this interpretation.  We report the accuracy of MRI in predicting pathological 
response to neoadjuvant epirubicin, cyclophosphamide and nab-paclitaxel in the 




primary cohort of NEONAB (Clinicaltrials.gov #: NCT01830244), a phase 2 study of 
tailored neoadjuvant therapy for breast cancer. We include in our analysis a subset 
of patients with HR-positive, HER2-negative tumours and RS ≥25 in addition to 
subsets defined by HR, HER2 and Ki67.  
MATERIALS AND METHODS 
NEONAB was a single arm phase II clinical trial of tailored neoadjuvant 
chemotherapy in stage II-III breast cancer. This trial was conducted across three 
centres in two states; University Hospital Geelong and South West Health Care 
Warrnambool in Victoria and Royal North Shore Hospital in New South Wales. 
Patients 
Between April 2013 and December 2015, patients presenting to one of the 
recruitment sites with stage II or III, unilateral, histologically confirmed invasive 
breast cancer were eligible. Prior to chemotherapy all tumours were assessed for 
oestrogen receptor (ER) and progesterone receptor (PR) status, considered positive 
if ≥1% of tumour cells stained for ER and/or PR. HER2 status was also assessed by 
immunohistochemistry and in situ hybridisation. Ki67 was assessed and recorded as 
equal to or greater than 15% or less than 15%. Patients with HER2-negative, HR-
positive cancers had RS assay performed. Patients were analysed by three receptor 
subgroups; patients with HR-positive, HER2-negative, RS ≥25 tumours (hereafter 
designated ‘HR-positive’), patients with HER2-positive tumours and patients with 
ER, PR and HER2-negative tumours i.e. triple negative breast cancers. Patients with 
HR-positive, HER2-negative, RS <25 cancers were treated as a separate cohort and 
excluded from this study. A separate subgroup analysis was performed on the total 
cohort divided into two groups defined by Ki67 status; Ki67 ≥15% and Ki67 <15%. 
This study was reviewed and approved by the relevant ethics committees. All 
patients signed written informed consent. 





Patients received epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 (EC) every 
3 weeks for 12 weeks; followed by nab-paclitaxel 125 mg/m2 days 1, 8, and 15 every 
4 weeks for 12 weeks. Trastuzumab 8mg/kg loading dose then 6mg/kg every 3 
weeks was added to nab-paclitaxel for HER2-positive patients and continued post-
operatively for a total of 12 months. Patients underwent mastectomy or breast 
conserving surgery and sentinel node biopsy or axillary dissection after completion 
of neoadjuvant therapy and reassessment of residual disease with MRI. 
Radiology & Pathology  
Magnetic resonance imaging of the breast was performed before and 2 weeks after 
primary systemic therapy. The MR imaging was performed on a Siemans 3T Verio 
Magnetom using dedicated software and a 16 channel AL dedicated breast coil 
except 3 studies which were performed on a Siemans 1.5T Aera with a 16 channel 
closed breast specific coil. Studies were performed utilising a dynamic contrast 
enhanced technique with axial acquisition, high resolution 3 plane reconstructions 
and 7.5ml Gadovist (gadobutrol) contrast agent injected manually according to a set 
timing protocol. The 3 North Shore Private Hospital studies utilised 10ml Multihance 
(gadobenate dimeglumine) in place of Gadovist. The sequences were: a fat 
suppressed sequence, a non-fat suppressed T2 sequence, the dynamic rapid 
sequence fat suppressed T1 sequence and a high resolution fat suppressed T1 
sequence. For the 3 studies performed at North Shore Private Hospital this last 
sequence was acquired in the sagittal plane. The data was further analysed using a 
CAD program to allow multiplanar and maximum intensity projection analysis, 
measurement and dynamic contrast enhancement analysis. Due to variation in 
methods of volumetric measurement of tumour-size, we measured the tumour in 3 
planes and used the longest diameter of tumour in millimetres as the size of the 
tumour on MRI. Multiple target lesions were recorded separately. Diffusion studies 
were performed but not used in this trial. Radiological response was determined by 




comparison of target lesions, a complete response was defined as resolution of all 
target lesions.  All MR studies in Geelong were double-reported by two breast 
radiologists, one of which was the central trial radiologist, LEW, who has expertise in 
breast imaging and MRI. MR studies from other centres were all reviewed by LEW.  
Pathological response was assessed by experienced local pathologists. Pathological 
complete response was defined as no residual invasive disease in breast with 
residual in situ disease permitted, ypT0/is.  
Statistical Analysis 
To evaluate the role of MRI in predicting pCR, diagnostic measures; sensitivity, 
specificity, PPV and NPV were calculated. The analysis was conducted on the entire 
cohort and by each disease subtype (HR-positive, HER2-positive and TNBC) and Ki67 
status.   
The Bland-Altman method was used to quantify the agreement between the 
measurements of size of residual lesions from the MRI and the measurements of 
the size of the tumours in the resection specimen. The difference between the two 
measurements from each patient was plotted against the average of the two 
measurements and the corresponding mean difference and limits of agreement 
(mean ± 1.96SD) were calculated. As the group sizes were too small to construct 
Bland-Altman plots for each subgroup, the plots were reproduced coding the 
observations by subgroup to visually assess the differences.  
 
RESULTS 
Patients and materials 
Patients’ baseline characteristics are described in Table 1. Forty patients were 
enrolled, one patient did not undergo radiological assessments therefore data were 
available in thirty-nine; 14 TNBC, 15 HER2-positive and 10 HR-positive patients. Ki67 
was evaluable in 34 patients, 26 Ki67≥15% and 8 Ki67<15%. Patients with Ki67<15% 




were present in all receptor subgroups. Radiological complete response was 
observed in 15 patients (38%); 6 TNBC, 7 HER2-positive, 2 HR-positive and pCR in 21 
patients (53%); 6 TNBC, 12 HER2-positive and 3 HR-positive. Four patients had 
radiological complete response on MRI with residual disease on pathological 
examination; 3 TNBC and 1 HR-positive (10%). 
Accuracy of MRI for predicting pCR 
MRI correctly classified 64.1% of patients in the primary cohort. MRI sensitivity and 
specificity were 52% and 78%, with corresponding PPV 73% and NPV 58%. MRI was 
most useful for predicting pCR in the HER2-positive subgroup where sensitivity was 
58%, specificity 100%, PPV 100% and NPV 38% Table 2. In HR-positive and TNBC 
patients MRI was less useful with NPV 75% and 62.5% respectively and PPV of 50% 
in both subgroups Table 2. Analysis of the cohort by Ki67 status showed MRI had 
higher PPV and NPV in tumours with Ki67 ≥ 15% than tumours with Ki67 < 15%, 75% 
versus 50% and 57.5% versus 50% respectively Table 3.  
Accuracy of MRI for predicting size of residual disease 
In the entire cohort the mean difference between MRI and pathology 
measurements was -1.65mm (SD 21.1); on average, MRI underestimated the 
residual tumour size. The lower and upper limits of agreement were -43.07mm and 
39.77mm Figure 1. Figure 2 shows the same Bland-Altman plot as in but Figure 1 by 
disease subtype. From inspection, there does not appear to be any pattern in the 
difference in measurements across the disease subtypes. The mean differences 
were 1.67mm (SD 10) for HER2-positive, -4.72mm (SD 28.1) for HR-positive and -
4.02mm (SD 26.3) for TNBC. Although this indicates MRI overestimated residual 
disease in HER2-positive cancers and underestimated disease in HR-positive and 
TNBC, these results should be interpreted with caution due to the small numbers in 
each of the subgroups. 
Figure 3 shows the Bland-Altman plot coded by Ki67 status which does not show 
any pattern in the difference in measurements between groups. The mean 




difference for Ki67 <15% was 1.35mm (SD 9.5) and Ki67≥15% was -3.08mm (SD 
25.9) but again, the small number of tumours in each group limits interpretation of 
these findings.  
DISCUSSION 
Assessment of residual disease after neoadjuvant therapy for breast cancer can 
involve several modalities including clinical examination, ultrasonography, 
mammography, functional imaging and MRI. MRI is deemed ‘optional’ by 
international guidelines, reflecting the lack of consensus regarding its utility in this 
setting8. Despite the controversies, in the clinic, MRI is often used to re-evaluate 
tumours and informs surgical plan in almost fifty percent of patients145. It is 
therefore imperative that the accuracy of this imaging tool is optimised and 
understood in context of individual tumour characteristics and biology. Our analysis 
of the agreement between MRI and pathologic measurements of residual disease 
demonstrated both under and overestimation occurred. Subgroup analyses were 
limited by small numbers but inspection of Bland-Altman plots did not reveal any 
biases. Overall, in keeping with previous studies, approximately 65% of our patients 
were correctly classified by MRI 20,32,146. Of those incorrectly classified, 10% of 
patients with radiological complete response had residual invasive tumour evident 
on pathologic examination. These patients are theoretically at risk of inadequate 
margins and the need for further surgery, however, overtreatment may also be a 
risk. When used for staging primary breast cancer, MRI often leads to more 
extensive surgery 7.In the neoadjuvant setting, McDermott et al found despite 
having a higher rate of pCR, patients who underwent post treatment MRI had a 
significantly lower rate of breast conserving surgery compared to those who did not. 
Twenty-five percent of our patients had residual lesions on MRI but achieved a pCR, 
overestimations that could have led to overtreatment.   
It has become evident that the accuracy of post-neoadjuvant therapy MRI is 
improved when analysed in the context of pre-treatment breast cancer 
subtype23,26,33,147. Further improvements in accuracy may be possible if 




interpretation is coupled to a better understanding of tumour biology incorporating 
markers like Ki67 index, genomic profile and radiological phenotype. The findings of 
this study are limited by the small number of patients in each subgroup. More 
definitive results would require a larger sample size to enable robust statistical 
analyses of the differences between these subgroups.  This limitation is present 
throughout the literature on this subject, a 2015 meta-analysis collated individual 
data from only three hundred patients across eight studies20. Inclusion of MRI in 
large prospective neo-adjuvant trials, exemplified by the I-SPY analysis, will provide 
more definitive answers in future research 33. Nevertheless, our results add to the 
evidence that post- neoadjuvant therapy MRI is likely more useful for predicting pCR 
in HER2-positive tumours, with PPV 100% in this subgroup. Recent evidence also 
indicates MRI has higher accuracy in TNBC but this was not seen in our analysis 
31,33,34,146,148. This is likely a reflection of the small number in our subgroups but 
examination of the individual cases also underlines the limitations of MRI in 
detecting microscopic residual disease. Notably, of the 3 TNBC patients with 
radiological complete response but pathological residual disease, 2 had near 
complete pathological response with very small foci of invasive cancer, 1.1mm and 
<5mm respectively. Our analysis measured the accuracy of MRI in predicting pCR 
whereas other studies have assessed MRI’s ability to predict a ‘clinically meaningful 
response’ defined as regression of tumour to a size permitting breast conserving 
surgery33. Whilst MRI was not useful in predicting pCR in our TNBC cohort, its utility 
in predicting ‘clinically meaningful response’ was not assessed and cannot be 
excluded. In our cohort of patients with HR-positive, HER2-negative, Oncotype DX® 
RS ≥ 25 tumours, the accuracy of MRI was similar to other studies’ HR-positive 
cohorts33,35,146. Given our small sample size and the problem of cross trial 
comparison, these findings should be interpreted with caution, however, in this 
study, the addition of genomic information did not appear to increase the accuracy 
of MRI compared to other unselected HR-positive cohorts.  




Previous reports have shown Ki67 index, independent of receptor subtype, can be 
used to identify tumours in which MRI has greater accuracy to predict pCR32,34,35. 
The proportion of cells staining for Ki67 provides an indication of a tumour’s rate of 
proliferation. In HR-positive cancers, a Ki67 index < 15% is occasionally used as a 
surrogate for molecularly defined luminal A subtype 114,115. In our analysis, MRI 
appeared to bemore accurate for predicting pCR in tumours with a higher 
proliferative index; PPV 75% for Ki67 ≥ 15% versus 50% for Ki 67 < 15%. This is a 
lower cut off than previous studies but still indicates the rate of proliferation of the 
primary tumour maybe relevant when interpreting MRI findings post- neoadjuvant 
therapy.  
There is no standard approach to the assessment of residual breast cancer after 
neoadjuvant treatment but the use of MRI can be refined by incorporating the 
individual patient’s tumour subtype and biology into the analysis. Recent studies 
suggest measures of tumour volume and contrast kinetic thresholds can also be 
used to increase the accuracy of post-NST MRI over traditional measurements of 
tumour diameter149,150. We propose the development of algorithms that incorporate 
receptor subtype, tumour proliferation and radiological phenotype into the 
interpretation of post-neoadjuvant therapy MRI33,151.  Our findings support the use 
of HER2 status and Ki67 index in such an assessment.  
CONCLUSIONS 
The role of MRI in the assessment of residual breast cancer post- neoadjuvant 
therapy is evolving. Our study suggests MRI maybe more accurate for predicting pCR 
in HER2+ disease than other subtypes and in cancers with higher Ki67 proliferative 
index. Whether more detailed knowledge of tumour biology, such as that gleaned 
from genomic biomarkers, could further inform the assessment of residual disease 
is a question for future research. 
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Table 1. Summary of Patient Baseline Characteristics 
Characteristic n % 
Age, years   
 Median 51 years 
 Range (35–77 years) 
Subtype   
    HER2+ 15 38 
    HR+, HER2-, RS ≥ 25 10 26 
    TNBC 14 36 
Ki67   
     ≥ 15% 26 67 
     < 15% 8 21 
     unknown 5 13 
Multifocalᵧ   
      Yes 21 54 
      No 18 46 
ECOG   
 0 38 98 
 1 1 2 
Ethnic group   
 Caucasian 36 93 
 Asian 3 7 
Tumour stage+   
 2a 10 26 
 2b 11 28 
 3a 14 36 
 3b 3 8 
 3c 1 2 
* HR status deemed negative if <1% nuclei staining, + American Joint Committee 
on Cancer Breast Cancer Staging v.7, ᵧMultifocal as per MRI Assessment 
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor 
receptor type 2 
  




Table 2. Accuracy of MRI for predicting pCR according to subtype 
 HER2-positive 
TNBC HR-positive, RS ≥ 
25 





































PPV: positive predictive value; NPV: negative predictive value 
 
Table 3. Accuracy of MRI for predicting pCR according to Ki67 status 
 Ki67 < 15% Ki67 ≥ 15% 


































Chapter 4.  
Whole-exome sequencing analyses of triple negative breast 
cancers pre- and post-treatment with neoadjuvant epirubicin, 
cyclophosphamide and nanoparticle albumin-bound paclitaxel.  
 
This chapter has been published as part of an extended manuscript that included 
the clinical outcomes of the NEONAB trial (Appendix B). Caitlin Murphy was the 
major contributer to the conceptual design of the project and was responsible for 
maintaining tumour inventory, DNA extraction, sourcing of the external sequencing 
provider, primer design and optimisation, validation of sequencing results, 
refinement of variant calling, variant analysis and interpretation of results. Caitlin 
was the principal author of the manuscript, co-authors provided comments and 
critical refinement.  
4.1 Preface 
Recent breast cancer studies that have harnessed the power of high-throughput 
sequencing paint a picture of a disease with significant genetic heterogeneity where 
all driver mutations, mostly occurring at very low frequencies, have now been 
described65. Despite this, genomic biomarkers that predict response to treatment 
for TNBC remain relatively elusive. Triple negative breast cancer is a diagnosis of 
exclusion, a subtype comprised of multiple disparate disease entities, loosely unified 
by the absence of HR expression and HER2 amplification. Consequently, the 
development of predictive biomarkers in TNBC has presented significant challenges. 
Germline BRCA1/2 inactivating mutations are the only predictor used in the clinic to 
identify a small subset of TNBC patients who benefit from additional DNA damaging 
agents. In metastatic disease these patients gain a modest clinical benefit from 
polyADP ribose polymerase (PARP) inhibitors and, in early stage disease, germline 
BRCA1/2 alterations may predict benefit from neo-adjuvant platinum 
chemotherapy152,153. Unlike HR positive disease, gene expression signatures 
developed in pre-clinical models have not translated into tools we can use in the 
clinic. Data suggest alterations in gene pathways contain more promise as predictive 
biomarkers than single gene mutations76,77. The presence of tumour infiltrating 




lymphocytes (TiLs) is prognostic in early TNBC but has not been validated as a 
predictive tool154. Studies of the mutational processes driving the acquisition of 
alterations in TNBC have produced a composite signature that may prove useful in 
defining more cancers that contain homologous repair deficiency (HRD) and thus be 
susceptible to agents targeting DNA repair94. Advances in the treatment of TNBC will 
rely on a more detailed understanding of the molecular profiles of post-treatment 
chemotherapy resistant disease. In this study we profiled a small cohort of primary 
TNBC treated with neo-adjuvant epirubicin, cyclophosphamide and nab-paclitaxel. 
Our aim was to describe genomic alterations in these tumours, comparing those 
that achieved pCR with those that did not, with the hypothesis that this may reveal 
potential mechanisms of resistance to the chemotherapy delivered.  We compared 
the pre-treatment diagnostic biopsies to the residual disease resected after the 
completion of chemotherapy and made a number of observations. First, residual 
disease bears closer resemblance to its primary tumour than the residual disease of 
other patients. Second, several markers of HRD, including base substitution 
signature 3 in the COSMIC classification155 and defects in the ATM signaling pathway 
were detected in these tumours. Finally, very few commonalities were identified, 
supporting the idea that mechanisms of resistance are individual to each cancer 
and, whilst data to support its use is still accumulating, with improvements in cost 
and efficiency, precision medicine utilizing whole exome sequencing to identify 
possible targets for individual patients in resistant disease may become a  useful 
tool in the clinic for the evaluation of TNBC.   
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In early breast cancer gene expression profiles in hormone receptor (HR) positive 
disease and human epidermal growth factor type 2 receptor (HER2) status define 
the benefit a patient is likely to receive from chemotherapy or targeted therapy and 
are therefore used to guide treatment90. For triple negative breast cancer (TNBC), 
except for the small minority of BRCA germline mutation carriers, no such predictors 
exist153. Both the inter- and intra-tumoural heterogeneity of TNBC pose significant 
barriers to the development of predictive markers and targeted therapies156. 
Nevertheless, further efforts to enhance our molecular understanding of these 
cancers are necessary to improve outcomes for patients with this disease.  
Advances in the speed, accuracy and accessibility of high-throughput sequencing 
has produced detailed description of the genomic landscape of primary breast 
cancer61,65,99. The molecular profile of residual disease post neo-adjuvant therapy is 
not as well documented or understood. Initially studies of neo-adjuvant therapies 
that included the assessment of residual disease focused on gene expression 
changes or were limited to targeted panels of fewer than two hundred genes9-11. 
More recent reports utilising whole exome or whole genome sequencing have 
increased our understanding, but the number of patients and tumours studied 
remains relatively small76,77,98.  
Although controversy still exists over the use of pathological complete response 
(pCR) as a surrogate endpoint in breast cancer trials, TNBC patients who achieve a 
pCR, in general, have excellent prognosis14,157. Neo-adjuvant studies provide an 
opportunity to examine the evolution of resistant cancers under the selective 
pressure of chemotherapy and determine how their genomic profiles differ from 
complete responders. The goal of our analysis was to describe genomic alterations 
present in a small group of primary TNBC, comparing those that achieved a pCR 
after treatment with anthracycline/taxane chemotherapy to those with residual 
disease. Equally, by identifying alterations that emerged in residual disease we 
aimed to study how these cancers evolved from their primary tumours. Our analysis 




of gene pathways and mutational signatures revealed evidence of homologous 
repair deficiency (HRD) in most tumour samples. Clonal evolution analysis 
demonstrated persistence and emergence of chemoresistant clones between 
diagnostic and residual disease. There were few commonalities identified amongst 
the TNBCs included in our cohort, underscoring the known genomic heterogeneity 
of this disease and the potential need for a personalized medicine approach to aid in 
the treatment of chemorefractory patients.  
Materials and Methods 
Patients, treatment and tumour samples  
The NEONAB trial recruited patients with previously untreated stage II or III, 
unilateral, histologically confirmed invasive breast cancer who attended for 
treatment at one of three institutions (University Hospital Geelong, South West 
Healthcare Warrnambool & Royal North Shore Hospital Sydney). Patients received 
epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 (EC) every 3 weeks for 12 
weeks; followed by nab-paclitaxel 125 mg/m2 days 1, 8, and 15 every 4 weeks for 12 
weeks. Patients then underwent mastectomy or breast conserving surgery and 
sentinel node biopsy or axillary dissection. 
Patients enrolled on the NEONAB study optionally consented to the use of their 
tumour tissue and blood for translational research. Formalin fixed paraffin 
embedded (FFPE) pre-treatment core biopsies of breast lesions and involved lymph 
nodes were obtained for diagnostic purposes and 20 paraffin scrolls of 10 micron 
thickness were provided for DNA extraction. For those patients who had an 
incomplete pathological response, FFPE samples of the residual disease were taken 
from the surgical specimen. Whole blood samples were available for germline DNA 
extraction.  
DNA extraction 




Genomic DNA was extracted from FFPE TNBC tumours using the ReliaPrepTM FFPE 
gDNA Miniprep System (Promega) according to the manufacturer’s protocol. The 
DNA was quantified using a Qubit dsDNA HS Assay kit and a Qubit® 2.0 Fluorometer 
(ThermoFisher). 
Library preparation and whole exome sequencing 
Libraries were prepared starting with 200ng DNA. For FFPE derived DNA, pre-
capture library was prepared using the ‘Agilent SureSelect XT Target Enrichment 
System with SureSelect XT-Adaptor Libraries’ (Version 2.5B). This protocol uses the 
KAPA Hyper Prep Kit (KAPA Biosystems, Version KR0961 – v1.14). DNA was purified 
using 1.8x AMPureXP beads. Libraries prepared from germline DNA derived from 
blood and all capture and post-capture steps were performed using the Agilent 
SureSelectXT Target Enrichment System according to protocol G7530- 90000, 
Version C0, December 2016. Whole Exome Sequencing was performed using the 
Illumina HiSeq 3000 system, Protocol 15066493. Four libraries per lane were pooled 
to achieve coverages of 150x for the diagnostic and residual disease samples. For 
the germline samples, libraries were pooled in a single lane to achieve coverages of 
50x. Library preparation and sequencing was conducted by the Monash Health 
Translational Precinct (MHTP) Medical Genomics Facility (Melbourne, Australia). 
Data processing and variant calling 
Twenty-seven paired-end samples (sixteen tumour samples and eleven germline 
samples) were mapped to the HG38 genome using Subread-1.5.3158. Only uniquely 
mapped fragments were reported, and short INDELs up to 16-base pairs (bp) in 
length were detected during read mapping. Single nucleotide variants were then 
called from the aligned sequence using exactSNP159; with maximum depth set to 
10000000 and minimum depth set to 30 for the germline samples, and 50 for the 
diagnosis and residual samples. An SNV was removed from further analysis if the 
coverage level at its chromosomal location was less than 20, or if in the matched 
germline sample, there was greater than 10% difference to the reference genome at 




that location.  This variant calling and filtering were performed by YL and WS at 
Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia). Further 
filtering excluded SNVs with a base quality score less than 20 and variant allele 
frequency (VAF) less than 10%. It was accepted that some rare, low frequency 
variants may be excluded from the analysis due to the stringency of these 
parameters.  
 
Variants were annotated using Variant Effect Predictor160 and non-synonymous 
SNVs (missense, stop-gained, splice site) were selected for gene and gene pathway 
analyses. For the gene and gene pathway analyses, variants assigned as intronic or 
intergenic were discarded. Variants were then categorised as high functional impact 
(HFI) variants if deemed likely to be deleterious or damaging by at least three of six 
functional prediction tools (SIFT, PolyPhen, PROVEAN, Mutation Taster, Mutation 
Assessor, LRT score)160.  
 
Insertion/deletions were called using the Subread aligner158 and results were filtered 
by five conditions. An INDEL must have at had at least twenty supporting reads in 
the sample where it was detected and at least five supporting reads where the 
INDEL is at least 25-bp away from both ends of the read. An INDEL must have at 
least twenty reads covering the same chromosomal location but have no INDELs at 
the same location in the matched germline sample. The matched germline sample 
could not contain any INDELs within a 50-bp region surrounding an INDEL detected 
in the tumour sample. Finally, an INDEL must have had a mismatch rate less than 
10% in the 10bp region in the sample where it was detected. Those with VAF less 
than 10% or annotated as intergenic or intronic were excluded. To minimize false 
positive calls INDELs adjacent to more than five repetitive regions were excluded. All 
INDELs were considered HFI. 
 
Variant validation 




To exclude sequencing artefacts, where DNA was available, HFI variants with a VAF 
greater than 20% were validated by Sanger sequencing. Primers were designed 
using NCBI Primer-Blast161, Integrated DNA Technologies OligoAnalyser tool162 and 
UCSC In-Silico PCR tool163 (Supplementary Table 1). Primers were tested and cycling 
conditions optimised prior to use on tumour samples. Tumour DNA underwent 35 
cycles of PCR amplification and adequate product was confirmed using gel 
electrophoresis prior to sequencing. Variants were manually reviewed using 




The number of bases deemed callable was determined using the GATK 
CallableLoci164 tool with a minimum depth set at twenty reads. Mutation burden 
was calculated as the total number of SNVs, including synonymous, intronic and 
intergenic variants and INDELs per Mb for each sample. A second analysis looking 
only at non-synonymous, splice site variants and INDELs was also performed. 
Statistical analysis was performed using Minitab v.17.1.0 package. Analysis of 
variance was performed using one way ANOVA test to compare mutation burden 
between diagnostic and residual disease samples as well as diagnostic samples that 
achieved pCR versus diagnostic samples that did not. A p-value less than or equal to 
0.05 was considered to indicate statistical significance.  
 
Gene pathway analysis 
Gene pathway analyses were conducted to assess the relationship between any 
genes that possessed HFI SNVs and INDELs. For each sample, gene lists were used as 
input in DAVID165,166 and analysed using the functional annotator. Enrichment in 
Biocarta and Kegg pathways was assessed using a modified Fisher’s Exact test. The 
null hypothesis was rejected at the 0.05 significance level. Significantly enriched 
pathways were manually reviewed in each sample and comparisons were made 




between diagnostic samples that obtained pCR and those that did not and between 
diagnostic and paired residual disease samples. Gene pathways are illustrated using 
cBioportal Oncoprint tool167. 
 
Mutational signature analysis 
Variants included in the mutational signature analysis had a VAF >10% and quality 
score > 20. Non-synonymous, intronic, intergenic and synonymous SNVs were all 
included in this analysis. Each was sample was individually analysed using 
DeconstructSignatures168 with default normalisation and minimum signature 
contribution of 0.06. Signatures detected in the NEONAB samples were referenced 
against the 30 signatures found in the latest COSMIC classification155.  
Clonal evolution analysis 
 
To identify clonal sub-populations in each tumour sample, clonal analysis was 
performed using superFreq169. Of the eleven patients, five had germline, diagnostic 
and residual disease samples available for analysis. These five patients’ samples 
were analysed using the germline data from the six patients who achieved pCR as 
controls. SuperFreq was run using default options according to the manual’s 
protocol. Clonal analysis was performed independently for each patient across the 
different sample condition types. These analyses were performed by DC and WS at 




Patients and Samples 
A total of 40 patients were included in the NEONAB primary cohort, three did not 
consent to the use of their tissue and two others withdrew consent. Tissue could 
not be obtained for three patients and two patients had multifocal disease with two 
diagnostic samples per patient available. In total thirty-four diagnostic and nineteen 
residual disease samples were obtained for analysis. There were fifteen TNBC 




diagnostic and eight residual disease specimens. These samples underwent DNA 
extraction. Adequate DNA (minimum 200ng) was extracted from eleven of the 
fifteen diagnostic and five of eight residual disease samples and these proceeded to 
library preparation and whole exome sequencing. Of the six patients who achieved 
pCR, none developed breast cancer recurrence or died whereas three of the five 
patients with residual disease have recurred and two of these patients have 
succumbed to their disease. 
 
Data processing, variant calling and variant validation 
Sequencing quality was above specification, more than 92% of reads achieved a Quality 
Score (QS) greater than 30 and the mean QS was 38. There was an average of 10 000 
somatic SNVs per diagnostic sample and an average of  13 500 SNVs per residual 
disease sample. After filtering for coverage, base quality, and minimum VAF,  
diagnostic samples contained an average of 203 SNVs (range 40 – 599) and residual 
disease samples contained an average of 143 SNVs (range 22 – 310). Annotation to 
determine functional impact yielded  an average of 30 HFI SNVs (range 5 – 101) per 
diagnostic sample and an average of 17 HFI SNVs (range 1 – 49) per residual disease 
sample. Stringent filtering removed the majority of INDELs, leaving an average of  88 
INDELs (range 49 – 200) called from the diagnostic samples and an average of 80 
INDELs (range 39 – 114) from residual disease. There was adequate DNA for variant 
validation in 10 of the 16 tumour samples. Ninety-four percent of SNVs (33/35) and 
72% of INDELs (5/7) were validated using Sanger sequencing. 
Variant burden 
The total number of variants ranged from 1.0 – 9.3 variants/Mb in the diagnostic 
samples and 0.70 – 4.6/Mb in the residual samples. Analysis of the number of non-
synonymous variants was similar; 0.72 – 4.6/Mb in the diagnostic and 0.60 – 2.3/Mb 
in the residual tumours. Overall, as expected given the small number of samples 
analysed, there was no difference in mutation burden between pre-treatment 




diagnostic samples and their matched post-treatment tumours (p = 0.78 Figure 1). 
Two patients exhibited an increase in variant load (N07, N08), another two 
remained stable (N09, N27) and one showed a reduction post treatment (N29). 
There was also no difference in variant burden between the group that achieved 
pCR and the non-pCR group, the mean number of alterations were 3.7/Mb vs 
2.9/Mb respectively (p = 0.54). The results were similar when the analysis was 
restricted to non-synonymous variants only with 1.9 variants/Mb for the pCR group 
vs 1.5 variatns/Mb for the non-pCR group (p = 0.38). 
 
Alterations in TP53 and SWitch/Sucrose Non-Fermentable (SWI/SNF) complex genes  
Consistent with the known heterogeneity of TNBC, most of the functional mutations 
identified in our samples were not recurrent. Alterations in TP53 were found in 
eight of sixteen tumour samples, six diagnostic and two residual disease. The 
specific type of alteration in TP53 varied from patient to patient and included both 
INDELs and missense SNVs. The same TP53 variants found in D07 and D27, were 
however, also found in their paired residual disease samples, R07 and R27. There 
was no association between TP53 alterations and chemotherapy response. 
Truncating mutations in ARID1A and ARID1B, genes encoding subunits of the 
SWI/SNF chromatin regulating complex, were identified in two residual disease 
samples, R09 and R07, that were not present in the matched diagnostic samples. 
Alterations in ARID1A, however, were also observed in D20 and D21, samples that 
did achieve pCR. 
 
Gene pathway comparisons and ATM signalling in chemo-resistant tumours 
Three of the five diagnostic samples (D08, D27, D29) from the non-pCR group were 
found to be significantly enriched for functional mutations in the Biocarta “ATM 
signalling pathway” (p < 0.05 Figure 2). Although alterations in this pathway were 
also identified in sample D07 and in five of six diagnostic samples from 
the pCR group, these did not reach statistical significance (p > 0.05). None of the 




paired residual disease samples retained this enrichment. Analysis of the diagnostic 
samples from the group that achieved pCR revealed several significantly enriched 
pathways but these varied from sample to sample with no commonalities identified 
(Supplementary Table 2). Similarly, analysis of the non-pCR group did not reveal any 
significantly enriched pathways shared across multiple samples. The small sample 
size precludes definitive comparisons between groups but the lack of commonalities 
seen between samples from different patients is consistent with the known genomic 
heterogeneity of this disease. 
 
Androgen-Signalling/FOXA1 pathway alterations 
Samples were examined specifically for alterations in the Androgen Receptor-
signalling/FOXA1 pathway. Patients whose tumours contain a single alteration in 
this pathway were previously reported to have a significantly higher likelihood of 
achieving pCR to neoadjuvant anthracycline/taxane chemotherapy in TNBC77. In our 
study the diagnostic samples from two patients who achieved pCR contained a 
functional mutation in this pathway but the same alterations were also found in 
three patients with post-treatment residual disease. Alterations in this pathway 
were not predictive of response to chemotherapy in our cohort. 
 
Mutational signatures 
Mutational base substitution signatures were identified in each diagnostic and 
residual disease sample. Usually seen in approximately 20% of breast cancers93, 
Signature 3 in the COSMIC classification was identified in 75% (12/16) of samples, 
nine diagnostic and three residual disease. This signature is associated with 
homologous repair deficiency (HRD). Initially identified in samples with germline and 
somatic BRCA1/2 variants, more recently it has also been found in tumours with 
epigenetic silencing of BRCA1 or homologous deletions of BRCA1/2170. None of the 
samples enriched for Signature 3 contained somatic BRCA1/2 variants in our cohort, 
suggesting other alterations contributed to enrichment of this signature. In a cohort 




of 992 breast cancers, Polak et al. demonstrated the majority of tumours highly 
enriched for Signature 3 did not carry inactivating BRCA1/2 variants but identified 
PALB2 variants and inactivation of RAD51C as alternative lesions associated with this 
signature’s activity170. Variants in other genes associated with HRD (Table 1), 
specifically CHEK2 and PTEN, were identified in five of our twelve samples with 
Signature 3 activity.  In our cohort Signature 3 was equally likely to be identified in 
diagnostic samples that achieved pCR as those that did not, suggesting no 
association with response.  
Signature 17 was identified in the residual disease of one patient, N29 (Figure 3). 
The aetiology of this signature is unknown, it is more dominant later in breast 
cancer tumourigenesis171 and has previously been described as arising in multiple 
treatment resistant metastatic lesions in one case of triple negative breast cancer 
resistant to both chemotherapy and a PIK3CA inhibitor101. Of note, both the 
diagnostic and residual samples from patient N29 harboured a HFI SNV in PIK3CA. 
Patient N29 in our study had only a partial pathological response to chemotherapy 
yet has remained recurrence free three years post-surgery. Signature 17 may derive 
from cells capable of surviving under the selective pressure of, in our case 
anthracycline/taxane chemotherapy and in the previous case a pan-PIK3CA inhibitor 
and thus be a marker of treatment insensitivity. 
Signatures 6, 20 and 26, associated with mismatch repair (MMR) and microsatellite 
instability were found collectively in eight of sixteen tumours. Of note, only one of 
these samples, D12, contained variants in the known MMR genes (Table 1) and 
higher than average variant burden at 9.2 variants/Mb. These signatures were 
present in both groups, those that attained pCR and those that did not, and do not 
appear to have any relationship to response to chemotherapy. 
 
Clonal analysis demonstrates persistence  and emergence of chemoresistant 
subclones  




Clonal evolution analyses confirmed populations evident in residual disease samples 
were descendent from subclones present in their matched primary cancers. This is 
consistent with previous reports evaluating primary and metastatic disease that 
suggest the emergence of resistant cells occurs through treatment induced clonal 
selection rather than chemotherapy induced mutagenesis98. 
 
Three patients with residual disease, N07, N08 and N27 developed disease 
recurrence after surgery. The majority of subclones present in D07 responded to 
chemotherapy and were undetectable in the residual disease. There was 
persistence of one dominant clone and emergence of four new subclones, one of 
which contained alterations in the known breast cancer driver NOTCH1 (Figure 4). 
Sample D08 contained only two subclones, one which responded to chemotherapy 
and was not detectable in R08. The persistent clone contained alterations in MED12, 
a transcriptional initiator, VAV3, involved in cytoskeletal rearrangements and 
transcriptional activation, neither of which are implicated in carcinogenesis or 
actionable targets. Patient NN27 experienced disease progression during 
neoadjuvant therapy and subsequently died of metastatic breast cancer within 
months of completing protocol treatment. Consistent with the lack of clinical 
response and the minimal change in mutation burden or gene pathway alterations, 
analysis of samples D27 and R27 showed relatively stable populations of subclones 
present in the diagnostic sample and the emergence of a single new subclonal 
population in the residual disease (Figure 5). This subclone contained missense 
mutations in the TP53 regulator MDM4, as well as FIP1L1, an oncogenic driver in 
prostate cancer, POU2AF1, a transcriptional activator in Hodgkins disease and 
frameshift mutations in IFI16 which modulates TP53 and RAS/RAF signaling. Other 
subclones persisting between D27 and R27 were identified by mutations in TP53 
itself and the driver mutation NCOR1. Taken together the mutational burden, gene 
pathway, mutational signature and clonal evolution analyses illustrate primary 




resistance to chemotherapy across multiple subclones, making the identification of 
targets for novel therapies particularly difficult in this case.  
Discussion 
In this study we have characterised the genomic profiles of a well-defined group of 
clinically annotated TNBC tumours prior to and following neoadjuvant 
anthracycline/taxane chemotherapy. Prior studies have demonstrated metastatic 
disease, when compared to its originating primary tumour, is typified by higher 
mutation load and acquisition of new driver mutations whereas synchronous lymph 
node metastases more closely resemble their originating lesion98,101. Underscoring 
the heterogeneity of TNBC, in our study, the variation observed between paired 
diagnostic and residual disease samples was markedly less than the variation 
between tumours from different patients. In our cohort, gene pathways and 
mutational signatures operating in the diagnostic specimens were mostly present in 
the matched residual disease, indicating a degree of denovo resistance. These are 
findings that serve to underscore the known heterogeneity of TNBC. Our analysis 
reveals that the residual disease, although altered, still bears close resemblance to 
pre-treatment tumour. This may simply be a function of the short, approximately six 
to seven month, time interval between biopsy and surgical resection but also 
suggests further acquisition of genomic alterations are necessary for the 
development of metastatic disease.  
 
Signature 3 was detected in the majority of samples from our cohort. The presence 
of this signature signals bi-allelic loss of BRCA1/2 or other alterations causing HRD170. 
Although we did not observe an association between the presence of Signature 3 
and response to anthracycline/taxane chemotherapy, three previous retrospective 
studies have shown some association between HRD, defined by BRCA mutation, 
BRCA methylation or HRD score, and response to standard neo-adjuvant 
anthracycline based chemotherapy77,172,173. It has been established in both breast 
and ovarian cancer that HRD defines a subset of tumours responsive to platinum 




chemotherapy and poly ADP ribose polymerase (PARP) inhibition174-176. In breast 
cancer, methods for defining HRD have focussed on the detection of germline and 
somatic mutations or epigenetic silencing of HRD genes and copy number 
alterations (CNA), large scale transitions or loss of heterozygosity in the tumour 
genome177. As yet, no one method for identifying HRD has emerged as clearly 
superior to any other. Mutational signatures that highlight INDEL and CNA 
alterations have now been developed and a composite signature, HRDetect, which 
incorporates base substitution, CNA and INDEL signatures has been validated as a 
marker of HRD and sensitivity to platinum chemotherapy94,178. Due to our small 
number of samples we were not able to perform an analysis using HRDetect but, 
with the presence of signature 3, four of the five patients with residual disease bore 
a marker of HRD. This raises the question of whether these patients may have 
benefited from intensification of chemotherapy with the addition of a platinum 
agent. Mutational signature tools like HRDetect have considerable potential for 
clinical use and warrant further investigation in clinical trials. If they emerge as a 
front runner amongst the various methods currently available for identifying HRD 
they may help target a subset of TNBC patients who could benefit from a DNA 
damaging agent such as a platinum or PARP inhibitor as part of their therapy.  
 
Our analysis of gene and gene pathway alterations permits several observations 
regarding TP53, ATM signalling and genes encoding subunits of the SWI/SNF 
complex. Mutations in TP53 are the most common recurrent alterations found in 
TNBC but their relationship to chemotherapy response remains unclear. Although 
pre-clinical data demonstrates an association between TP53 mutation and 
anthracycline resistance, clinical studies have produced conflicting results67,98,179. Our 
observation is consistent with more recent studies showing no relationship to 
response or resistance. ATM signalling is a crucial biological pathway by which the 
cancer cell mediates its response to double stranded DNA breaks and enacts DNA 
repair180. As such, alterations in this pathway are a potential cause of HRD. This 




pathway was enriched for functional mutations in three of the five patients with 
residual disease, although sample size limits insight into whether ATM signalling 
alterations differentiate responders from resistant tumours. These alterations are, 
however, further evidence of HRD in these tumours and again raise the question of 
whether there would be a benefit to intensifying treatment with the addition of a 
platinum drug in these patients. The SWI/SNF chromatin regulating complex is one 
of the most common mediators of carcinogenesis, with mutations, translocations 
and deletions present in approximately 20% of all cancers181. More recently, Yates et 
al.98 have reported the emergence of SWI/SNF complex mutations in breast cancers 
resistant to taxane chemotherapy, an observation mirrored in a separate study of 
ovarian tumours182. In our cohort, ARID1A and ARID1B mutations were identified in 
the residual disease of two patients, R09 and R07, that were not found in the 
matched diagnostic samples. Through its effects on chromatin remodelling, gene 
silencing and cell differentiation the SWI/SNF complex acts in multiple ways as a 
tumour suppressor183. The ARID1A and ARID1B subunits have an antagonistic effect 
on cell cycle progression and mutations with functional impact in these subunits are 
potential targets for new therapies183,184. Specifically, ARID1A deficient cells, due to 
defective cell cycle regulation, are reliant on ATR checkpoint activity. Pre-clinical 
work has identified ARID1A deficiency as a biomarker for the efficacy of ATR 
inhibitors and, in ovarian cancer cells, the multi-kinase inhibitor dasatinib184,185. 
Alterations in the SWI/SNF complex genes have now also been reported to confer 
resistance to immunotherapies in melanoma and renal cell cancers186,187. Alterations 
in ARID1A were also found in two chemosensitive samples, D20 and D21. These 
mutations alone may not discriminate between tumours that will achieve pCR and 
those that will not but their presence in resistant disease may identify cancers 
sensitive to a novel targeted agent. Defects in the SWI/SNF complex in 
chemoresistant tumours merit further investigation, most importantly as there are 
now methods of targeting these defects emerging from pre-clinical studies184,185.  




Prior studies have shown the origin of breast cancer metastases can be traced to 
subclones present in the primary tumour but it is not yet possible to identify 
prospectively which subclone provides the metastatic seed98,99,101. Comparative 
examination of the subclonal structure of primary and residual disease allows 
exploration of likely candidate clones that may give rise to metastatic spread due to 
their ability to persist or emerge under the selective pressure of neo-adjuvant 
chemotherapy. Identification of these clones and personalizing further therapy 
based on any targetable drivers, mutational processes or pathways they contain 
could provide an opportunity to eradicate the disease prior to the development of 
incurable metastatic spread. Identifying which patients with residual disease are at 
sufficiently high risk of developing metastases and would benefit from further 
intensification of therapy requires significant further research. 
  





Our analyses of primary TNBC pre and post neoadjuvant chemotherapy reiterates 
the known genomic heterogeneity of this disease. Acknowledging the limitations 
imposed by small sample size, a few hypothesis generating observations can be 
made. Though few commonalities are identified, both our gene pathway and 
mutational signature analyses detected faults in HRD in both primary and residual 
disease. Clearly defining HRD in TNBC, potentially with the use of mutational 
signatures, may enable us to target patients with residual disease that are most 
likely to benefit from prospective studies investigating the addition of DNA 
damaging agents such as platinum or PARP inhibitors to standard therapy. This 
project reinforces our understanding that TNBC, in genomic terms, is a subgroup 
comprised of often only loosely related cancers. In future, with further advances in 
the cost and efficiency of WES technologies, a precision medicine approach may be 
used to identify individual patients with targetable tumour defects.  




Table 1. Genes associated with HRD or MMR  

























Figure 1. Variant burden. Box-plot showing the A. total nunmber of variants per Mb or B. non-synonymous 
variants per Mb in diagnostic samples that achieved ‘pCR’ compared to those that did not: ‘non-pCR’.. C. Boxplot 
depicting the total number of variants per Mb or D. non-synonymous variants per Mb in diagnostic samples 
from five patients who did not achieve pCR compared to the matched residual disease samples from the same 
five patients. A one-way ANOVA was performed and the corresponding p-values are displayed. 
 
 Figure 2.  Functional mutations in the ATM signalling pathway. OncoPrint of variants detected in 
five genes central to the ATM signaling pathway. The percentage samples affected by variants in each 
gene are noted and missense (green) and truncating (black) mutations are presented. 
  





Figure 3. Mutational signature analysis. Signature 17 is highlighted in sample R29. Signature 1 is age 
related and is the predominant signature in this sample. Signature 17 contributes to ~13% mutation 
burden.  
  





Figure 4. River plot depicting the clonal structure and evolution of diagnostic and residual disease 
samples from patient N07. The plot demonstrates persistence of one dominant subclone and 
emergence of four new subclones in the residual disease. 
  






Figure 5. River plot depicting the clonal structure and evolution of diagnostic and residual disease 
samples from patient N27. The persistence of four subclones (blue, brown, green, orange) and the 
emergence of a new subclone (pink) despite treatement with neo-adjuvant chemotherapy is 
depicted.  
  




Supplementary Table 1: Primer sequences for variant validation 
PRIMER SEQUENCE 
AM362_KMT2Dex34-R1 GCA GGT CAA ACT CGT CTC CA 
AM361_KMT2Dex34-F1 CTT CCC CCA CAG AAA CCC TC 
AM360_ARID4Bex17-R1 AGC TAA AAC TCA AGT TAC CTC ACA T 
AM359_ARID4Bex17-F1 CCT GGA ACA ATC ACA GCC A 
AM358_PDLIM3ex8-R1 ATC TGC ACA ATC CTT CTG CCC 
AM357_PDLIM3ex8-F1 CTC GTT TTC TTC CCC AAC AGC G 
AM356_ATRNex10-R1 GGC AAA AAG ATG CCT GAA GAG A 
AM355_ATRNex10-F1 TGG TTG TGC TTG CAT TAG CAG 
AM354_LRP8ex1-R1 GCT TTG TTG GTG GCT AGG G 
AM353_LRP8ex1-F1 CGA GCG TCA CCG AAC CT 
AM352_CASP8ex12-R1 GTG TAA CAG TGA GGA GGG CTG 
AM351_CASP8ex12-F1 AGG CTT GTC AGG GGG ATA AC 
AM350_MSH3ex1-R1 TCA CCC AAT TTG TAG CCC CG 
AM349_MSH3ex1-F1 GCG GTT TTG AGC CGA TTC TT 
AM346_STAMPBex4-R1 TTT TGA GTT TCT GGT CTT TGC CC 
AM345_STAMPBex4-F1 TGT TGC AGT CAC CAA CTT GAC 
AM344_TRIOex19-R1 CAA CGT GCA GGC TCC TTT TG 
AM343_TRIOex19-F1 ACC AGC AGG TGG CCA GAT A 
AM342_FAT4ex9-R1 TGT CCT TGT CCA TTG CCG AA 
AM341_FAT4ex9-F1 CGG ACC ACT AAA CGG AGC TT 
AM340_ZMAT3-R1 AGG GCA AGT TGA CAA AAG GC 
AM339-ZMAT3ex6-F1 ATC TCT TGC TTT AGC AGG TCC TTA C 
AM338_GABBR2ex7-R1 AAC AGC CCC TCT TTT GCT TT 
AM337_GABBR2ex7-F1 CTG ATG TCC CTG CCG AGT A 
AM336_DAPK1ex3-R1 CTG GAA CGA AGA TGC CAG C 
AM335_DAPK1ex3-F1 CAG TGG ACA GTT TGC GGT TG 
AM334_PTPRQex27-R1 TCT CCT AAT GCC TTC TCT CTT CTC 
AM333_PTPRQex27-F1 TAA GCT GGA GTG AAC CTG CTG 
AM332_LRRK2-R1 AAT GAG AGC TGT CCT CTG TCG 
AM331_LRRK2ex44-F1 ACA GTT TTA GGT TTT GCT TGA CAG A 
AM330_TP53-R1 CAA CCA GCC CTG TCG TCT 
AM329_TP53ex7-F1 GAG GTG CTT ACG CAT GTT TGT 
AM328_ARID1Bex1-R1 GCT TCG CCA ACG GTT TTC AG 
AM327_ARID1Bex1-F1 CCC CGT CAC GAA CTC AAC AT 
AM326_SETD1Aex8-R1 GCT CCA AGG AGT TCA CAA AGT CA 
AM325_SETD1Aex8-F1 GAT GAG AAA GTA GGG CTT GGG T 
AM324_SLC22A4ex1-R1 CGC AGG GAG TCT CAA GGG 
AM323_SLC22A4ex1-F1 GGA CTA CGA CGA GGT GAT CG 
AM322_NCOR1ex31-R1 GAT AAC TCA CAG GGG TCC TCC 
AM321_NCOR1ex31-F1 GCC AGA TGA CTT TGC TAC CTG T 




AM320_INPP4Aex5-R1 GCT TCA GCT ACA GAT GCA CAA G 
AM319_INPP4Aex5-F1 ACT TCC CTG TGA CAA CTG ACG 
AM318_INF2ex13-R1 CAC TCA CTT TCG CAG GCA G 
AM317_INF2ex13-F1 AGT CCT TCC CCT CAA AGT GTG 
AM316_INF2ex15-R1 CTA GAC GGA GCC CTG AGA CA 
AM315_INF2ex15-F1 AGC TGA TCC TGA GAA TTG GGA A 
AM314_SF1ex9-R1 AAG AGG TCA ATG CAA GGG AAC A 
AM313_SF1ex9-F1 AAG GCA GTG GAA CAG GTG AG 
AM312_SOX9ex1-R1 TAC CTC CAG AGC TTG CCC AG 
AM311_SOX9ex1-F1 CGA GCC CGA TCT GAA GAA GG 
AM310_WDPCPex12-R1 GGA GAT GGA CTG TTA GGA AAC ACA 
AM309_WDPCPex12-F1 TGC AAA ACC TGA CTG ACT GC 
AM308_ARID5Bex10-R1 GGT AGG TTT GTG CGG GTT CT 
AM307_ARID5Bex10-F1 CCT CTA CAG ACA CAC CGA GC 
AM306_FSHRex10-R1 AGG GAG GCA GAA ATG GCA AA 
AM305_FSHRex10-F1 CCA TCT TTG GCA TCA GCA GC 
AM304_GATAD1ex5-R1 TAC AAA TGG TTG GCA ACT GAT TCC 
AM303_GATAD1ex5-F1 TAT TTA ACC TTT CCC TTG GCT GC 
AM302_DCAF13ex10-R1 GGT GAG ATG AGA GCA GAA GTC A 
AM301_DCAF13ex10-F1 AGT GCT TGC AGA GCT AGT GT 
AM300_PTK2-R1 TTC TGT CCT TTT CCT CTT CTG GA 
AM299_PTK2ex7-F1 GAT GCC TCT CCC CCA GTT TT 
AM298_RAB3GAP1ex15-R1 AAT TCC TGC CAG AGG TGT G 
AM297_RAB3GAP1ex15-F1 AAA TCT TGA AAA TGT GGG ACT TCC T 
AM296_TP53ex16-R1 GGG ACA GCT TCC CTG GTT AG 
AM295_TP53-F1 TCT TGT TCC CCA CTG ACA GC 
AM294_CICex11-R1 AAT CTC CCC CTC TCT CAA GC 





















Sample  Category Pathway Term 
Gene 
Count P-Value 
D07 KEGG_PATHWAY Transcriptional misregulation in cancer 5 0.0056 
D08 BIOCARTA ATM Signaling Pathway 2 0.026 
D27 BIOCARTA ATM Signaling Pathway 3 0.024 
D27 BIOCARTA Cell Cycle 3 0.033 
D27 BIOCARTA 
Control of Gene Expression by Vitamin 
D Receptor 3 0.036 
D27 BIOCARTA Cell Cycle 3 0.046 
D27 KEGG_PATHWAY Chronic myeloid leukemia 6 0.00054 
D27 KEGG_PATHWAY Hepatitis B 7 0.0023 
D27 KEGG_PATHWAY Prostate cancer 5 0.0092 
D27 KEGG_PATHWAY Pathways in cancer 10 0.011 
D27 KEGG_PATHWAY Thyroid hormone signaling pathway 5 0.022 
D27 KEGG_PATHWAY Glioma 4 0.023 
D27 KEGG_PATHWAY Pancreatic cancer 4 0.023 
D27 KEGG_PATHWAY p53 signaling pathway 4 0.025 
D27 KEGG_PATHWAY Cell cycleFriday2018a 5 0.029 
D27 KEGG_PATHWAY HTLV-I infection 7 0.033 
D27 KEGG_PATHWAY Proteoglycans in cancer 6 0.039 
D29 BIOCARTA 
Tumor Suppressor Arf Inhibits 
Ribosomal Biogenesis 3 0.03 
D29 BIOCARTA ATM Signaling Pathway 3 0.04 
D29 KEGG_PATHWAY mTOR signaling pathway 4 0.014 
D29 KEGG_PATHWAY PI3K-Akt signaling pathway 8 0.029 







Neo-adjuvant systemic therapy results in equivalent survival outcomes and offers 
research opportunities not afforded by traditional adjuvant therapy2. Consequently 
NST is now an accepted standard treatment for the management of early stage 
TNBC. Neo-adjuvant systemic therapy and the use of pathological response as an 
FDA approved endpoint for the development of new drug therapies has driven 
innovation in trial design and provided new opportunities for clinical and 
translational research143. Window of opportunity studies, where patients undergo 
biopsy and are treated for a short period with an investigational agent prior to 
standard therapy, have emerged as a favoured method of studying the molecular 
response of breat cancer to both exisiting and novel therapies188. The ISPY trials, in 
particular ISPY-2, represent a new method of rapidly assessing the promise of new 
agents as they emerge from pre-clinical and phase I studies to result in statistically 
and clinically meaningful outcomes on phase III  testing139,140,189. Ultimately, NST and 
the opportunity it provides for assessing a tumour’s response to therapy may allow 
clinicians to alter treatment strategies based on these response assessments190. This 
thesis comprised a number of projects embedded within the NEONAB trial, a phase 
II NST study in EBC, that provided the necessary infrastructure for the realisation of 
the clinical, imaging and translational work reported here.  
Chapter 2 reported the clinical outcomes of NEONAB. Tailoring neo-adjuvant 
systemic therapy and the use of the agent nab-paclitaxel was safe, feasible and 
resulted in high pathological response rates in comparison to historical controls. 
From the patient’s perspective, NST may improve cosmetic outcomes by allowing 
those with good response to undergo more conservative excisions or breast 
conserving surgery in place of mastectomy. NEONAB found the rate of mastectomy 
versus breast conservation to be in line with and  acceptable by current standards. 




Chapter 3 focussed on radiological response assessment  in NEONAB. Magnetic 
resonance imaging has an established role in the screening of high risk women and 
the primary staging of breast cancers but, in the absence of a definitive cost/benefit 
advantage, it is used inconsistently in the assessment of breast cancer response to 
NST7,191. Our findings support the use of MRI in this setting but with the caveat that 
the imaging findings should be interpreted in concert with the pre-treatment 
clinicopathological characteristics of the primary tumour. Future advances in 
functional imaging and the use of volumetric measurement may further improve the 
accuracy and therefore the utility of MRI in the assessment of residual disease149,150.  
Using the tumour samples collected from patients in NEONAB’s primay cohort, the 
third project in this thesis was a pilot study that examined the molecular alterations 
evident in triple negative breast cancers before and after treatment with neo-
adjuvant anthracycline/taxane chemotherapy. We described a series of cancers 
that, although clinically classified as a single subtype, genomically, bore limited 
resemblance to each other. The results of our analyses reinforced the picture of 
TNBC as a genomically heterogenous disease. Despite these tumours harbouring 
few commonalities, we found markers of HRD present in the majority of our 
samples. Homologous repair deficiency represents a defect that has already been 
targeted in ovarian and breast cancer and is being actively explored as a target in 
clinical trials that include prostate, glioma and pancreatic cancers192-194. In metastatic 
breast cancer, women with germline BRCA mutations gain a progression free 
survival benefit from treatment with a PARP inhibitor and in neoadjuvant studies of 
early breast cancer, the addition of platinum in these patients increases pCR 
rates152,153. Current methods of identifying germline BRCA-wild-type patients with 
tumours harbouring HRD vary from study to study. These methods include the 
detection of somatic HRD gene defects and large scale transitions or loss of 
heterozygosity in the tumour genome177.We detected HRD defects in our mutational 
signature and gene pathways analyses. Mutational signatures, in particular the 
composite signature, HRDetect represent an innovative and effective way of 




identifying HRD and may prove to be clinical useful if found to be predictive of 
platinum or PARP inhibitor benefit in prospective trials94,178. More definitive 
conclusions require a far larger number of tumour samples to be analysed. Future 
studies addressing these questions, embedded within large phase clinical trials, 
should provide the opportunity to study these cancers in much greater numbers. In 
a disease as genomically diverse as TNBC, large sample sizes will be required to 
detect meaningful alterations with the potential to influence therapy. Since this 
project was conceived, recognising that the genomic heterogeneity of TNBC will 
always pose a significant barrier to the implementation of targeted therapies, there 
has been increased focus on harnassing an immunomodulatory approach to treating 
this disease. A phase III clinical trial has now demonstrated a benefit with the 
addition of immunotherapy to chemotherapy in advanced disease and trials in early 
stage breast cancer are recruiting195. 
This thesis brings together the clinical, radiological and translational outcomes of 
the NEONAB trial and places them in the wider context of current EBC research and 
drug development. We have demonstrated that, despite the significant logistics 
involved in a translational research project, it is feasible to conduct this type of 
study through regional cancer centres.  The findings of our studies support further 
research into the use of genomic markers to guide NST in EBC, the role of MRI in the 
reassessment of disease post NST and the targeting of HRD in the treatment of 
TNBC. It is not inconceivable that, with further advances in cost and efficiency, WES 
to personalise treatment within this genomically disparate group of tumours, may 
be a tool used in future to improve outcomes for TNBC patients.   
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